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1. Abstract 
Background: Atherosclerosis is a chronic inflammatory disease in which oxidative stress and 
macrophages play fundamental roles. Macrophages are heterogeneous cells in term of 
morphology and function and the prevalence of a specific morpho-phenotype may influence the 
progression or the regression of the plaque. Human coronary plaque macrophages are not easily 
obtainable and monocyte-derived macrophages (MDMs) are widely accepted as a good 
surrogate. Our previous study has reported that healthy subjects show two dominant MDM 
morphotypes, spindle and round, present in the same percentage.  
Aim: The aims of the study were to assess the biochemical and functional profile of MDMs 
obtained from CAD patients and to investigate the relationship between these characteristics 
and plaque features detected in vivo. 
Material and methods: ninety CAD patients and twenty-five healthy volunteers were enrolled. 
MDMs were obtained by culturing monocytes for 7 days in medium supplemented with 10% 
autologous serum. Transglutaminase2 (TG2), tissue factor (TF), nuclear factor erythroid 2–
related factor 2 (Nrf2) and heme-oxygenase (HO-1) were determined by western blotting and 
immunofluorescence. The uptake of apoptotic Jurkat T cells was detected by flow cytometry and 
thrombin formation was assessed by thrombinoscope. Fatty acids composition and oxidative 
stress status, determined as the ratio between the reduced and oxidized forms of glutathione 
(GSH and GSSG, respectively) were analyzed by liquid-chromatography tandem mass 
spectrometry (LC-MS/MS). Plaque features were detected in vivo by optical coherence 
tomography (OCT). 
Results: MDMs obtained from CAD patients were characterized by the predominance of round 
cells. These cells exhibited a lower efferocytic capacity and higher capacity to generate thrombin 
in respect to those of healthy subjects, reflecting the low expression of TG2 and the enhance of 
TF levels. Moreover, MDMs of CAD patients showed a higher oxidative stress status, evidenced 
by the lower GSH/GSSG ratio, in respect to those of healthy subjects. Finally, we found a positive 
correlation between oxidative stress status and membrane fluidity (MFI) as evidenced by the 
ratio of C18:1 (oleic acid)/C18:2 (linoleic acid), as well as MFI and capacity to engulf apoptotic 
cells. Regarding OCT analysis, patients with a higher round MDMs prevalence exhibited more 
frequently a lipid rich plaque, a TCFA (thin cap fibroatheroma), a greater intra-plaque 
macrophage content, and a ruptured plaque, characteristics of vulnerable plaque. Furthermore, 
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patients with high TF levels more frequently presented a intra-plaque macrophages 
accumulation, a ruptured plaque and a presence of thrombus. In addition, vulnerable plaque 
characteristics were associated with high HO-1 levels. 
Conclusions: MDMs of CAD patients present a pro-inflammatory and high thrombogenic profile 
in respect to those of healthy volunteers. The high oxidative stress present in these cells 
influences the membrane fluidity that in turn influences the efferocytic capability. This specific 
cellular profile detected in in vitro obtained MDMs is associated with the detection of high-risk 
and rupture-prone coronary plaques in vivo, at OCT investigation.  
Different MDM phenotypes might be novel diagnostic and therapeutic target able to counteract 
the progression of atherosclerosis. 
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2. Riassunto 
Razionale: Lo stress ossidativo e l’infiammazione svolgono un ruolo fondamentale in tutti gli 
stadi della patologia aterosclerotica. I macrofagi sono cellule caratterizzate da un’elevata 
eterogeneità morfologica e funzionale e la prevalenza di un determinato fenotipo può 
influenzare la progressione e/o la regressione della placca. Nell’uomo, i macrofagi della placca 
coronarica non sono facilmente ottenibili e i macrofagi ottenuti per differenziamento in vitro di 
monociti (MDM) sono considerati un buon surrogato. Un precedente studio condotto nel nostro 
laboratorio ha evidenziato che gli MDM ottenuti da soggetti sani si presentano come una 
popolazione morfologicamente eterogenea con cellule tonde e cellule lunghe presenti in egual 
misura. 
Obiettivo: Delineare un profilo biochimico e funzionale e definire la prevalenza dei due diversi 
morfotipi (a cellule lunghe e tonde) dei macrofagi ottenuti dal differenziamento di monociti 
isolati da pazienti con patologia coronarica (CAD). Inoltre, nei pazienti queste caratteristiche 
saranno messe in relazione con le caratteristiche della placca coronarica analizzata in vivo. 
Materiali e metodi: Sono stati arruolati 90 pazienti CAD e 25 soggetti sani. Gli MDM sono stati 
ottenuti in seguito al differenziamento dei monociti isolati dal sangue periferico e coltivati per 7 
giorni in terreno contenente il 10% di siero autologo. I livelli di transglutaminasi 2 (TG2), di 
fattore tissutale (TF), del fattore di trascrizione nucleare eritroide-2 (Nrf2) e di eme ossigenasi 
(HO-1) sono stati valutati mediante western blotting e immunofluorescenza. L’efferocitosi di 
queste cellule è stata analizzata mediante citofluorimetria a flusso e la formazione di trombina 
mediante trombinoscopio. Gli acidi grassi e lo stress ossidativo, valutato come rapporto tra la 
forma ridotta del glutatione e quella ossidata (GSH e GSSG, rispettivamente), sono stati analizzati 
mediante cromatografia liquida accoppiata a spettrometria di massa. Le caratteristiche della 
placca sono state valutate in vivo mediante tomografia ottica a coerenza di fase (OCT). 
Risultati: Gli MDM ottenuti dai pazienti CAD sono caratterizzati da una prevalenza di cellule 
tonde. Queste cellule mostrano una ridotta efferocitosi con più bassi livelli di TG2, e da una 
maggior capacità di generare trombina che riflette i più alti livelli di TF presenti. Inoltre, gli MDM 
ottenuti dai pazienti CAD mostrano livelli di stress ossidativo più alti, evidenziati da un basso 
rapporto GSH/GSSG, rispetto a quelli ottenuti dai volontari sani. Infine è stata osservata una 
correlazione positiva tra la fluidità di membrana (MFI), espressa dal rapporto tra acido 
oleico/acido linoleico, e lo stress ossidativo, così come tra MFI e la capacità efferocitica. L’analisi 
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della placca mediante OCT, ha evidenziato che i pazienti con una aumentata prevalenza di cellule 
tonde presentavano più frequentemente una placca ricca in lipidi, un cappuccio fibroso sottile, 
un alto contenuto di macrofagi intra-placca e una placca lesionata, caratteristiche tipiche della 
placca vulnerabile. Inoltre, i pazienti con livelli di TF più alti presentavano un maggiore accumulo 
di macrofagi intra-placca, una placca rotta e la presenza di trombo. Infine, è stato osservato che 
la vulnerabilità di placca si associa con più alti livelli di HO-1.   
Conclusioni: Gli MDM dei pazienti CAD presentano un profilo pro-infiammatorio e pro-
trombotico rispetto a quello dei soggetti sani, e un alto livello di stress ossidativo associato ad 
alterazioni della fluidità della membrana. Questo specifico profilo riscontrato negli MDM 
ottenuti in vitro risulta essere associato con la presenza di placche ad alto rischio e prone alla 
rottura evidenziate mediante OCT. I diversi fenotipi macrofagici potrebbero quindi 
rappresentare un nuovo bersaglio diagnostico e terapeutico per contrastare la progressione 
dell’aterosclerosi. 
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3.1 Atherosclerosis  
 
3.1.1 Definition 
Atherosclerosis (the term derives from the Greek word ἀρτηρία (athere), meaning gruel (lipid’s 
accumulation), and σκλήρωσις (sclerosis) for hardening) is currently considered as a chronic 
inflammatory disease in which immune mechanism interact with metabolic risk factors to 
initiate, propagate, and activate lesions in the arterial tree [1].  
3.1.2 Etiology 
The cause of atherosclerosis is still unknown but many epidemiological studies have identified 
several risk factors that can contribute to the pathogenesis of the disease. In particular, 
atherosclerosis risk factors can be classified into two categories, non-modifiable or modifiable: 
a) Non-modifiable risk factors:  
- age: atherosclerosis is an age-related disease; the incidence is lower in people under 40 
years, and increased in elderly people [2]  
- sex:  women generally have a lower risk for developing cardiovascular disease (CVD) 
compared to men of similar age [3] but this protection is lost during menopause 
suggesting the importance of sex steroid hormone signaling [4] 
- family history of premature coronary heart disease:  genetic predisposition to developing 
atherosclerotic disease is related to alterations of genes involved in lipid, sugar and 
amino acid metabolisms. For example, subjects with a gene mutation in LDL lipoprotein 
receptor, a pathological condition known as familial hypercholesterolemia, have 
cholesterol levels twice that of the normal population and they are at high risk to 
develop cardiovascular disease [5]. 
b) modifiable risk factors: 
- lifestyle and diet: a diet rich in animal protein and saturated fat, cholesterol, sodium and 
sugar associated with a sedentary lifestyle can contribute to increase the incidence of 
atherosclerosis [6]. Epidemiological studies have shown that cardiovascular disease is 
higher in western countries than in the eastern ones, where a diet with low calories 
intake, low in saturated fat and high fiber content, is followed [7]. An unbalanced diet 
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can favor the insurgence of various pathological conditions associated with 
atherosclerosis such as diabetes and insulin resistance, obesity and hypertension. 
- hyperlipidemia:  cholesterol is transported by several classes of lipoproteins, such as  
very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density 
lipoprotein (HDL). High levels of plasma cholesterol are related to a high synthesis of LDL, 
which levels are related to the onset of atherosclerosis [8].  
- hypertension: the mechanism through which hypertension can promote the onset and 
the progression of atherosclerosis is still unclear, but it is known that the increase in 
blood pressure can lead to endothelium damage, with the  subsequent  increase in the 
permeability and the retention of LDL in the vessel wall. In addition, hypertensive 
patients exhibit elevated levels of angiotensin II, a vasoconstrictor mediator that is 
involved in the atherosclerotic process [9].  
- smoke: according to World Health Organization data, smoke is responsible for 10% of all 
CVD cases [10]. Smoke plays a strong role not only in CVD initiation but it also 
contributes to disease progression and fatal cardiovascular outcomes. The key processes 
in smoking-induced atherogenesis initiation are endothelial dysfunction and damage, 
increase in oxidation of proatherogenic lipids, as well as decrease of HDL. Moreover, 
smoke induces inflammation and tissue factor (TF) expression that contributes to shift 
toward a procoagulant status [11]. 
- diabetes: hyperglycemia induces non-enzymatic glycosylation processes that may alter 
the lipoprotein structure and exert adverse effects on the vascular endothelium, 
promoting an oxidative stress condition [12]. In addition, insulin resistance was 
associated with hypertriglyceridemia and low levels of HDL. The increase in circulating 
levels of insulin favors the onset and the development of atheromasic plaque by inducing 
vascular wall changes, by promoting smooth muscle cell (SMC) proliferation and 
activating cholesterol synthesis [13]. 
 
3.1.3 Formation and development of atherosclerotic plaque 
The first step of atherosclerotic plaque formation is the endothelium dysfunction (ED). Vascular 
endothelium has a pivotal role in the modulation of vascular function and structure, mainly 
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through the synthesis of nitric oxide (NO). Thereby, many pathophysiological states, mainly by 
reducing endothelium-dependent vasodilation, evoke ED [14]. ED is defined an early phase as 
endothelial activation, a switch from a quiescent phenotype toward one that involves host 
defense response. ED is caused by an increase in radical oxygen species (ROS) generation (free 
oxygen radicals, superoxide anions and peroxides) and a reduction of NO bioavailability in 
vascular endothelium. At moderate concentrations ROS act as signaling molecules and play an 
important role in the regulation of vascular tone, oxygen sensing, cell growth and proliferation, 
apoptosis, and inflammatory responses [15]. In contrast to these regulatory functions under 
physiological conditions, excessive or sustained ROS production, exceeding the available 
antioxidant defense systems, leads to oxidative stress. Radical species mediate the endothelium 
nitric oxide synthase (eNOS) “uncoupling” that is responsible of the generation of superoxide 
rather than NO [16]. Another mechanism responsible for the reduction of NO is via the 
regulation of the levels of the NO synthesis inhibitor asymmetric dimethylarginine (ADMA) [17]. 
In particular, ROS reduce the activity of dimethyl arginine dimethyl aminohydrolase (DDAH), 
protein involved in the catabolism of ADMA, upregulate the expression of protein methyl 
transferases, enzymes involved in ADMA production, resulting in increase ADMA levels [17]. 
Also, vascular inflammation is highly associated with ED and plays a major role in the 
development of atherosclerosis. 
ED induces the increase of the endothelium permeability causing the retention of LDL into the 
intima of the vessels. At this level, LDL may undergo to oxidative modification by ROS from 
surrounding cells and modified LDL participate to the activation of the endothelial cells [18]. 
Healthy endothelium does not interact with leukocytes; however, activated endothelial cells 
express adhesion molecules and secrete chemoattractant signals leading to the recruitment of 
leukocytes from the bloodstream at the site of damage [19]. Among the molecules that are 
involved in cell adhesion, the selectin family, specifically E- and P-selectin, is responsible for the 
early attachment of leukocytes. One of the mechanisms involved is represented by the 
interaction between monocyte P-selectin glycoprotein ligand-1 and the endothelium. Monocytes 
are anchored to the endothelium through the endothelial intergrins vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [19]. In response to the 
accumulation of modified LDL into the intima, activated edothelium secretes several molecules, 
such as the chemokine monocyte chemoattractant protein-1 (MCP-1), that promote the 
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infiltration of monocytes into the vessel wall [18, 20]. At this level, monocytes differentiate into 
macrophages under the action of different stimuli, particular macrophage colony-stimulating 
factor [21]. Monocyte derived macrophages (MDM) uptake modified lipoproteins via scavenger 
receptors, resulting in the formation of lipid laden macrophages known as foam cells. The 
accumulation of foam cell is the very first event for the formation of early fatty streak [22]. 
Subsequent chemokine and cytokine secretion by foam cells and resident vascular wall cells 
induces the migration of SMC from the media into the intima [23]. This migration and the 
consequent proliferation leads to the secretion of extracellular matrix molecules, such as 
collagen, proteoglycans and elastin fibers, which are involved in the formation of the fibrous cap, 
which covers and stabilizes the plaque. Plaque stability depends on cap thickness and its thinning 
can provoke the plaque rupture. This event promote the exposure of the necrotic core, 
consisting of lipids, numerous macrophages and SMCs, to the blood flow of the artery causing 
thrombus formation and often leading to artery occlusion, cardiac event, myocardial infarction 
or stroke [24]. 
 
3.1.3.1 Classification of atherosclerotic lesion 
The atheromatous plaques have been reclassified in the 1990s by the American Heart 
Association (AHA) Consensus Group [25]. This latter classification includes six categories: type I, 
adaptive intimal thickening; type II, fatty streak; type III, transitional or intermediate lesions; 
type IV, atheroma; type V, fibroatheroma; type VI, complicated plaques with surface defects, 
and/or hematoma-hemorrhage, and/or thrombosis (Figure 1).   
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Figure 1. AHA classification of  atherosclerotic plaques. 
Type I lesion: consists of atherogenic lipoproteins and mononuclear cells infiltration at the intima 
level. The histological changes are minimal and consist in thickening of the vascular wall. Type I 
lesions have been described in most infants and children. 
Type II lesion: is characterized by fatty streaks formation. This lesion consist of macrophage, 
foam cells, and smooth muscle cells infiltrated into the intima. The extracellular space contains 
small quantities of lipid droplets and vesicles. The arteries of children generally contain type II 
lesions as the only grossly visible lesions. 
Type III lesion: is also known as intermediate lesion. It is characterized by the presence of visible 
extracellular lipid droplets and particles.  
Type IV lesion: is also defined atheroma. It is characterized by the presence of the lipid core 
containing macrophages, smooth muscle cells, lymphocytes and mast cells. Frequently these cell 
types are more concentrated in the limits of lesion. 
Type V lesions: are also known as fibroatheromas. They are lesions in which new fibrous 
connective tissue has been formed. There are different type of lesions:  
 type Va: lesions may be multilayered with the presence of  lipid cores close into the 
media, separated by thick layers of connective tissue; 
 type Vb: lesions containing a large amount of calcium and increased content of fibrous 
connective tissue;  
 type Vc: lesions where the normal intima is replaced and thickened with fibrous 
connective tissue, while lipid is minimal or absent.  
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Type VI lesion: is also known as complicated lesions. It is a type IV or V lesion in which 
disruptions of the lesion surface, hematoma or hemorrhage, and/or thrombotic deposits are 
present. Type VI lesions may be subdivided into:   
 type VIa: with the presence of disruption of the surface;  
 type VIb : with the presence of hematoma or hemorrhage; 
 type VIc: with the presence of thrombosis;  
 type VIabc: with the presence of all three features.  
 
3.1.4 Clinical manifestation of atherosclerosis 
In the recent decades, cardiovascular diseases have become the leading cause of morbidity and 
mortality worldwide [26]. CAD, also known as ischemic heart disease includes several clinical 
states of the disease: stable angina (SA), unstable angina (UA), myocardial infarction, and sudden 
cardiac death [27]. A common symptom is chest pain or discomfort which may travel into the 
shoulder, arm, back, neck, or jaw. SA is characterized by chest pain that occurs regularly with 
activity, after eating, or at other predictable times and is associated with narrowings of the 
arteries of the heart. SA patients present a partial occlusion of coronary artery with consequent 
reduction of myocardial perfusion. They present normal electrocardiogram (ECG) between the 
attacks, with a temporary ST segment depression during the events, but do not present blood 
biomarker of myocardial infarction such as troponin and creatine kinase-MB (CK-MB) increase. 
Angina that changes in intensity, features or frequency is termed unstable. UA is characterized 
by the presence of chest pain in rest condition and may precede myocardial infarction. It is 
distinguished from myocardial infarction without ST segment elevation for the absence or the 
modest increase in myocardial necrosis markers [28]. Myocardial infarction is due to a limited 
blood flow to the heart that cause ischemia (cell starvation secondary to a lack of oxygen) of the 
myocardial cells. The cause of blood flow limitation is atherosclerotic plaque growth, which 
protrudes into the channel of the artery, causing a partial obstruction. Myocardial infarction 
present two acute clinical manifestations: myocardial infarction that presents with the ST-
segment elevation (STEMI), the most severe condition, and the one that does not present with 
the ST-segment elevation (NSTEMI). STEMI represents a complete occlusion of a coronary artery 
leading to full-thickness myocardial infarction, and its diagnosis is based on the presence of ST-
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segment elevation on the electrocardiogram (ECG) that meets specific STEMI criteria [29]. In 
NSTEMI patient there is not a total occlusion of the vessel but there is myocardial cell death. 
From a diagnostic point of view, these patients can be identified by ECG changes [28].  
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3.2 Macrophages 
Macrophages, identified for the first time at the end of 19th century by Metchnikoff by their 
phagocytic nature, are cells belong to immunity system. They have key roles not only in 
immunity but also in numerous biological processes from development, homeostasis, and tissue 
repair to inflammation [30].  
3.2.1 Origin 
In 1960s van Furth observed that all macrophages derived from a pro-monocyte present in the 
bone marrow [31]. Nowadays, it is well established that tissue macrophages derives not only 
from monocytes that differentiate in the tissue and are unable to proliferate, but also may have 
an embryonic origin with the capacity of in situ self-renewal [32]. MDMs originate in the bone 
marrow from hematopoietic stem cells (HSCs) that differentiated toward more committed cell 
population. In detail, the master regulator PU.1 induces the differentiation of HSCs into common 
myeloid progenitors (CMP) through the inhibition of c-Myc [33]. Moreover, PU.1 through the 
activation of colony stimulating factor-1 (CSF-1) and IL-34 [34] not only directs lineage 
commitment of HSCs toward CMP but also of granulocyte-macrophage progenitors (GMP) 
toward monocyte-macrophage DC progenitors (MDP). Monocytes originate from MDP 
afterwards inflammatory stimulus through a chemotactic mechanism [35] (Figure 2). 
  
 
 
 
 
 
 
 
Figure 2. Origin of macrophages 
 
The release of monocytes from the bone marrow into the blood stream involves the chemokine 
receptor 2 (CCR2) and its ligand chemokine (C-C motif) ligand 7 (CCL7). Monocytes have been 
considered as a homogenous cell population until the late 1980s, when Bernward Passlick, 
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Dimitri Flieger and Löms Ziegler-Heitbrock demonstrated  for the first time the existence of 
distinct subsets of monocytes [36]. Today, circulating monocytes are classified into three main 
populations based on the different expression of surface markers, chemokines, and adhesion 
molecules [37]. The majority of circulating monocytes belong to the ‘classical monocytes’ that 
are characterized by high expression of CD14 receptor (that is involved in the recognition of 
lipopolysaccharide (LPS)) and no expression of CD16 (immunoglobulin Fcγ receptor). These 
monocytes CD14++CD16- show high phagocytic capacity and high myeloperoxidase activity. 
Moreover, they are big cells in term of size and are able to produce high levels of ROS and 
interleukin 6 (IL-6). CD14+CD16++ , known as ‘non classical’ monocytes, are smaller in term of 
size as compared to the ‘classical’ and they express high levels of fraktaline (CX3CR1) and C-C 
chemokine receptor (CCR) type 5 ; conversely, they do not express CCR2 and they produce 
tumor necrosis factor-α (TNF-α) and interleukin (IL)-1. Thus, this subpopulation present pro-
inflammatory characteristics.The number of ‘non classical’ monocytes is higher in subjects 
affected by acute inflammation [38], obesity [39], hypercholesterolemia [40] and CAD [41]. The 
‘intermediate’ monocytes, CD14+CD16+, share some characteristics with ‘classical’ monocytes 
and others with ‘non classical’. In particular, they express CCR1, CCR2 and C-X-C chemokine 
receptor (CXCR) 2 that are present in ‘classical’ monocytes but not in ‘non classical’, and they 
express CX3CR1 and CCR5 that are express by ‘non classical’ but not by ‘classical’ monocytes. 
Furthermore, ‘intermediate’ monocytes are characterized by a high inflammatory potential and 
they produced TNF-α and IL-1 after stimulation with LPS.  
Monocytes circulate in the bloodstream for about one to three days and then migrate, through 
the endothelium, into the intima where they differentiate into macrophages and participate to 
local immune defense [31]. Under physiological conditions, macrophages represent about 10-
15% of total number of cells present in the organism and this percentage can grow in response 
to inflammatory stimuli. Macrophages play a fundamental role in immunity response: they are 
involved in killing pathogens, in the elimination and degradation of apoptotic and necrotic cells, 
in the uptake of cellular debris and toxic molecules [42]. Moreover, they have a key role in 
inflammation and in the resolution of inflammation and in tissue repair [43]. 
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3.2.2 Macrophages heterogeneity 
Tissue macrophages have different nomenclatures and functions that are peculiar of the tissue 
where they are localized. In particular, bone macrophages are known as osteoclasts and are 
highly specialized in bone resorption [44]. Alveolar macrophages are present in the lung and are 
responsible for recycling of surfactant molecules [45]. The brain macrophages (microglia) sustain 
the brain development through trophic functions (regulation of neuronal precursor and 
production of neurotrophic factors) [46]. Kupffer cells in the liver ensure protection during 
infections and maintain iron homeostasis [47]. In the skin, macrophages (also known as 
Langerhans cells) are involved in the immune functions and in the epidermis/skin homeostasis 
[48]. In the spleen, red pulp macrophages are involved in the processing of heme and iron from 
senescent erythrocytes [49], while macrophages in the splenic marginal zone are important for 
the capture of blood-borne antigens [50]. Macrophages in the bone marrow have a crucial role 
in the retention of HSCs into bone marrow itself [51]. Intestinal macrophages in the muscularis 
mucosae are involved in the crosstalk with surrounding muscle cells and enteric neurons to 
ensuring normal intestinal peristalsis [52]. Resident macrophages maintain and control the tissue 
homeostasis, and, an alteration of steady state leads to a recruitment of high number of 
inflammatory cells that can change microenvironment inside the tissues. Macrophages are cells 
with great plasticity and they can easily change their phenotype inside the tissue in relation to 
microenvironmental changes. In response to the stimulus, macrophages are activated through a 
polarization towards two opposite states, the M1 or classical, and the M2 or alternative 
activation [53, 54]. M1 activation is induced by pathogens, wall components of bacterial cell, 
lipoproteins and cytokines such as interferon gamma (IFN-γ) and TNF-α. In particular, 
macrophages M1 show high microbicidal capacity [55] and secrete pro-inflammatory cytokynes 
like IL-1β, IL-6, IL-23 and TNF-α. Moreover, they are able to degrade the extracellular matrix 
(ECM) and they present high levels of major hystocompatibility complex (MHC) proteins [53]. 
The M2 activation is induced by fungal cells, parasites, immune complexes, complements, 
apoptotic cells, macrophage colony stimulating factor (M-CSF), IL-4, IL-13, IL-10, and trasforming 
growth factor-β (TGF-β) [55]. Macrophages M2 show high phagocytic capability and are involved 
in tissue repair and tissue remodeling [56, 57]. Moreover, the M1/M2 paradigm is not able to 
define the complexity and plasticity of mononuclear phagocytes, indeed in vivo, macrophages 
can adopt a variety of functional phenotypes depending on continuous changes in the tissue 
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microenvironment. Therefore, the M1/M2 macrophages description may be taken as a 
simplified framework describing a continuum of several functional states, of which M1 and M2 
activation states represent the two extremes [54]. In addition, M2 population has been further 
classified into M2a-d macrophages based on inducing agents, marker expression and 
functionality irrespective of tissue residence. In particular, the M2a is induced by IL-4 and IL-13 
and express high level of the mannose receptor (CD206), the decoy receptor IL-1RII and release 
IL-1 receptor antagonist. M2b macrophages are obtained after exposure to immune complexes 
and Toll-like receptor (TLR) agonists or IL-1 receptor ligands; they show the typical M2 
characteristics, but also produce pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 [58]. 
After IL-10 and glucocorticoids stimulation we have the highly efferocytic M2c macrophages that 
are characterized by the expression of pentraxin-3 and high amounts of TGF-β and IL-10. 
Moreover, they display high levels of the Mer receptor kinase (MerTK), which is crucial for their 
intense efferocytic activity [58, 59]. Finally, the stimulation of adenosine A (2A) receptor by TLR 
agonists induces the differentiation of macrophage into M2d phenotype. Adenosine signaling 
suppresses TNF-α, IL-1 and IFN-γ expression and confers a pro-angiogenic profile to 
macrophages, inducing the expression of vascular endothelial growth factor (VEGF) and IL-10 
[60]. 
3.2.3 MDMs in atherosclerotic disease 
3.2.3.1 Recruitment of monocytes and transmigration in the atherosclerotic plaque 
During all stages of atherosclerotic disease, macrophages and T-lymphocytes mediate the 
inflammatory response, whereas neutrophils and granulocytes that are less present in 
atherosclerotic plaques less contribute to this process [61].  Moreover, as previously mentioned, 
monocytes and macrophages are involved in all steps of lesion development like lipids 
accumulation, releasing of pro-inflammatory factors and cytokines, and ECM remodeling. A 
chronic inflammatory state enhances the recruitment of monocytes and lymphocytes from the 
blood circulation and favors their proliferation inside the plaque. At plaque level, the presence of 
growth factors and cytokines determines the monocytes differentiation into macrophages. The 
subsequent uptake of oxidized LDL (ox-LDL) induces the transformation of macrophages into 
foam cells [22] which contribute to the formation of the necrotic core, a typical feature of 
advanced lesions [62]. Monocytes penetrate into the subendothelial space through a process 
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called diapedesis which requires the activation of a complex system of interactions between 
adhesion molecules and chemotactic factors. The adhesion molecules involved in the endothelial 
recruitment of monocytes belong to four families: selectine, immunoglobulins, integrins and 
glycoproteins (mucin-like). The family of selectine, transmembrane monomeric glycoproteins, is 
composed by several classes, that differ for their localization. L-selectin, or CD62L, is expressed 
at leukocytes surface levels, interacts with the endothelium ligands  and allows transient 
adhesion; E-selectin (or CD62E) is present on cytokine activated endothelial cells, and binds the 
sialylated carbohydrate groups of proteins on the leukocyte surface; P-selectin (or CD62P) is 
localized both on endothelial cells and platelets. P-selectin under physiological conditions, is 
present at intracellular compartment in secretion granules; during inflammation the release of 
chemical mediators stimulates its translocation on the cell surface making it available for 
interaction with leukocyte ligands [61]. In addition, member of immunoglobulins superfamily, 
such as VCAM-1 and ICAM-1, are express on the endothelial surface and represent ligands for 
leukocytes integrins [63]. Integrins are heterodimeric transmembrane receptors formed by α 
and β subunits: monocytes express integrins β1 that recognize VCAM-1, and integrins β2, LFA-1 
and Mac-1 that bind ICAM-1. Also the α4β1 integrin known as VLA-4 (very late antigen -4) plays 
an important role in adhesion of monocytes to the endothelial surface, through the binding to 
some fibronectin isoforms and VCAM-1 [61, 64]. Macrophages localization in the atherosclerotic 
lesion contribute to the recruitment and to the migration of monocytes; in fact they secrete 
cytokines such as TNF-α and IL-1, that induce expression of ligands for integrins, especially 
VCAM-1 and ICAM-1, on endothelium. In response to lipid oxidation, macrophages also produce 
chemokines (chemotactic cytokines) such as MCP-1 (or CCL2) involved in the recall and amplify 
of the recruitment process of circulating monocytes in the arterial wall [65]. 
3.2.3.2 Differentiation of monocytes in the two different macrophage phenotypes  
Monocytes differentiate into macrophages inside the intima of vessels. The atherosclerotic 
plaque is characterized by a heterogeneous macrophage population that reflects the complexity 
and diversity of the microenvironment to which the cells are exposed after crossing the vascular 
wall. The presence of cytokines and growth factors during the monocytes differentiation process 
of monocytes induces polarization towards different phenotypes that have very different 
properties, even opposed. As previously mentioned, M1 macrophages have pro-inflammatory 
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characteristics, and when stimulated with LPS or interferon γ, they produce IL-1, IL-6, IL-8, IL-12 
and TNF-α. These cytokines, by activating endothelial cells and SMCs, enhance endothelial 
dysfunction state and promote oxidative stress [66]. While M1 macrophages promote necrotic 
core expansion and favor plaque development [67], the M2 phenotype is characterized by the 
presence of CD163 scavenger receptor and CD206 [68] that have an atheroprotective role. 
Moreover, they secrete TGF-β and anti-inflammatory cytokines such as IL-10 and reduce 
recruitment of pro-inflammatory cells [68]. Distribution of macrophages subpopulation in 
atherosclerotic lesions is different. It has been observed that murine lesions at an early stage 
contain predominantly M2 macrophages, whereas advanced lesions exhibit a predominance of 
M1. This evidence suggests that macrophages can modify their phenotype as a result of changes 
in the microenvironment present in the atherosclerotic plaque [69]. In contrast, in human 
atheromas, the phenotype M1 and M2 appear to be simultaneously present throughout the 
evolution of the plaque, as evidenced by a recent study on different lesion stages even if with 
different localization [70]. Specifically, M1 macrophages are localized mainly at rupture-prone 
site of the plaque, whereas there is no significant difference in the prevalence of the two 
subpopulations in the fibrous cap. On the contrary, a prevalence of M2 macrophages has been 
described at the level of the avventitia [70]. 
3.2.3.3 Foam cells formation 
A critical event in atherogenesis is the focal accumulation of lipid-laden foam cells derived from 
macrophages, smooth muscle cells and other vascular cells with subsequent fatty streak 
formation. Macrophages-derived foam cells play a central role in the atherogenic process as 
modulators of both lipid metabolism and the immune response [71]. The initiating effect in 
atherosclerosis may be the accumulation of LDL in the subendothelial matrix [62]. Accumulation 
is greater when levels of circulating LDL are raised, and both the transport and retention of LDL 
are increased in the sites of lesion formation. LDL trapped in the subendothelial matrix may also 
aggregate contributing to foam cell formation [50]. Modified LDLs are uptaken by macrophages 
and lead to generation of foam cells [72]. This uptake is mediated by a family of scavenger 
receptors (SRs) [73]. In detail, class A SRs (SR-AI, SR-AII, SR-AIII), class B SR (CLA-1/SR-BI, SR-BII, 
CD36), and the class D receptor CD68 are thought to be the most important ones during foam 
cell formation. In fact, they mediate the uptake of modified LDLs [74] and the engulfment of ox-
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LDL itself induces the expression of SR-A and CD36 SRs [75], which may provide a positive 
feedback mechanism that could amplify foam cell formation.  
3.2.3.4 Macrophage proliferation 
The macrophages proliferation within the atherosclerotic lesion could contribute to the growth 
and development of the atherosclerotic plaque [76]. Ox-LDLs are able to induce cell proliferation 
and their effect on macrophages has been demonstrated in several in vitro studies [77-79]. Ox-
LDLs play a detrimental role in the development of atherosclerotic lesions due to their active 
components such as lysophosphatidylcholine [80], apolipoprotein (Apo)-B and oxidized 
phospholipids [81] that can trigger various intracellular mechanisms associated with 
proliferation. Concerning this one, ox-LDLs are known to induce transient expression of mRNA 
encoding for GM-CSF, resulting in an increased secretion of this growth factor through a 
mechanism that is dependent on protein kinase C (PKC) activation [82]. The involvement of PKC 
in cell proliferation was demonstrated in in vitro models in which macrophages showed a 
reduced proliferation induced by ox-LDL after treatment with PKC-inhibitors [83]. 
3.2.3.5 Macrophage apoptosis 
Macrophages are involved in another important process that contributes to plaque 
development: the apoptosis [84].  
In 1992 Kerr and colleagues coined the term “apoptosis” that refers to a certain type of 
programmed cellular death. Apoptosis is characterized by several cell modification that include 
cell rounding, pseudopodia retraction, cell volume reduction, chromatin condensation, nuclear 
fragmentation with a minimal, if not absent, structural modification of cytoplasmic organelles. 
Apoptotic cell death is an important process during all atherosclerosis development. In fact, at 
plaque level, several cell types are involved in apoptosis: vascular cells, such as endothelial cells 
and smooth muscle cells, but also immune system cells such as T lymphocytes and macrophages 
[85]. In particular, macrophages represent approximately 40% of the apoptotic cells present 
within the plaque [86]. Moreover, the amount of apoptotic cells present in the atherosclerotic 
lesion is closely related to the evolution stage of the lesion: in general, the adaptive thickening of 
the intima and the fatty streak contain few apoptotic cells, while advanced lesions show real 
apoptotic foci [87]. Apoptotic process can be induced by numerous factors that are involved in 
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the atherosclerotic process. These ones include high levels of intracellular free cholesterol and 
ox-LDLs, pro-apoptotic cytokine production such as TNF-α, release of high amounts of free 
radicals of oxygen (ROS) by macrophages and hypoxia [88]. The consequences of the apoptotic 
process on the atherosclerotic lesions depend on the cell types involved, their location, and the 
lesion grade. At this regard, apoptosis of endothelial cells in contact with the bloodstream may 
favor plaque erosion with subsequently onset of a thrombotic event [89] as well as SMC 
apoptosis can contribute to destabilization of fibrous cap and can lead to plaque rupture [90]. 
Macrophages present within atherosclerotic plaque contain high amount of apoptotic material 
and cellular debris as a result of an active phagocytosis but the increase number of apoptotic 
cells can derive from an impairment of their clearance.  
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3.3 Efferocytosis 
Efferocytosis is specifically refered to the phagocytosis of apoptotic cells. The difference 
between efferocytosis and pathogens phagocytosis is the lack of phagocytic pro-inflammatory 
response. Indeed, efferocytosis is an anti-inflammatory process because prevent apoptotic cells 
transformation into necrotic cells, with subsequent secretion of cytotoxic mediators, and reduce 
the release of anti-inflammatory mediators such as TGF-β and IL-10 [91]. Moreover, 
efferocytosis inhibits the release of pro-inflammatory cytokines like TNF-α by macrophages [92]. 
Hence, this process protects tissue from inflammation and immunogenic response to the post-
apoptosis necrosis. The apoptosis is part of the physiological cells replacement, so a ready 
elimination of apoptotic cells is needed to maintain tissue homeostasis. Many cell populations 
are involved in this process, not only “professional phagocytes” like macrophages and dendritic 
cells, but also endothelial cells, SMC and fibroblasts.  
During the efferocytic process, it is possible to distinguish different steps: the recruitment of 
phagocytes to the apoptotic cell, the recognition of apoptotic cells, the uptake of the cells and 
the phagocytic response. In detail, when cells undergo apoptosis, they release soluble mediators, 
also known as “find me” or “eat me” signal, that are able to recruit phagocytes [93]. Among the 
“find me” signals, fractalkine, lysophosphatidylcholine (lysoPC), sphingosine-1-phosphate (S1P) 
and triphosphate nucleotides (adenosine triphosphate (ATP) and uridine triphosphate (UTP)) 
have been included. The fractalkine is a soluble protein that is associated to cell membrane and 
it is released from apoptotic cells. It is recognized by CX3CL1 receptor expressed on the 
phagocytes surface, and this interaction promotes efferocytosis process [94]. LysoPC has been 
the first “find me” lipid signal identified: it is expressed on apoptotic cells due to the caspase-3 
mediated activation of the calcium-independent phospholipase A2.  This signal interacts with 
G2a receptor (a G protein coupled receptor) that induce the phagocyte migration toward 
apoptotic cells [95]. S1P is also a lipid molecule that origin from the phosphorylation of 
sphingosine by sphingosine kinase 1. It acts both as “find me” and “eat me” signal and it has 
both anti-inflammatory and atheroprotective functions [96]. The interaction between SP1 with 
his receptor S1P-R1 present on phagocytes membrane diminishes plaque inflammation though 
the promotion of cyclooxygenase-2 mRNA stabilization and protein expression in macrophages, 
a prerequisite for PGE2 formation [97]. Recently, a new class of “find me” signals has been 
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identified. ATP and UTP belong to this class and it has been observed that apoptotic cells release 
these nucleotides through caspase-3/7–activated hexameric pannexin-1 channels exposed on 
their surface [98]. Extracellular nucleotides ATP and UTP act as “find me” signals to promote cell 
clearance by stimulating recruitment of motile phagocytes expressing P2Y purinergic receptors 
and also by causing upregulation of phagocytic receptors [99, 100].  
As regards to “eat me” signals, they translocate on membrane surface of cells that undergo to 
apoptosis, and promote the interactions between apoptotic cells and phagocytes. To date, many 
“eat me” signals have been identified and among them phosphatidylserine (PS) is the most 
studied.  
The structure of the membrane of apoptotic cells is different from that of the integral ones: the 
first changes occurring during apoptosis is the PS translocation to the external surface of cells. 
Under physiological conditions, PS is localized on the inner side of cell membrane; conversely, in 
apoptotic cells, PS is transported on the external side of cell membrane through the action of a 
translocase ATP-dependent. There are many receptors expressed from phagocytes that are able 
to recognize PS on apoptotic cells and, among them, four are the best studied: brain specific 
angiogenesis inhibitor (BAI) 1, T-cell immunoglobulin mucin receptor (TIM), Stabilin, and CD300. 
The G-protein–coupled receptor BAI1 directly binds PS via a series of N-terminal 
thrombospondin repeats and subsequently stimulates actin polymerization and phagocytosis via 
recruitment and activation of the Elmo-Dock bipartite Rac-GEF [101]. The TIM family are type I 
cell surface glycoproteins that bind PS via N-terminal IgV domains to mediate apoptotic cell 
engulfment [102]. Of the seven human CD300 genes, three have been shown to bind PS and 
modulate efferocytosis: CD300A, CD300B, and CD300F [103]. In particular, CD300A inhibits 
phagocytosis of apoptotic cells. Accordingly, macrophages treated with siRNA specific for 
CD300A exhibit a higher efficiency in the engulfment of apoptotic cells compared with 
macrophages that have been treated with non-target siRNA [104]. CD300B signaling, via the 
adaptor protein DAP12, positively regulates efferocytosis. Finally, CD300F is required for 
phagocytosis of apoptotic cells via recruitment of p85α of the PI3K signaling pathway [105]. 
There are numerous molecules that facilitate the interaction between PS expressed on the 
apoptotic cell membrane and the receptors present on the phagocytes surface. Among these, 
the most investigated ones are the epidermal growth factor MFGE8, the growth arrest-specific 
gene 6 protein (Gas6) and the plasma-protein β2- glycoprotein 1 (β2-GPI). MFGE8 mediate the 
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binding between PS and vitronectin integrin receptors ανβ3 and ανβ5 present on macrophages 
[106]. Gas6 bind Tyro-3-Axl-Mer (TAM) family (that are tyrosine kinase receptor) play a crucial 
role in the efferocityc process. In particular, it has been demonstrated that his depletion leads to 
the accumulation of apoptotic cells, to the extension of necrotic core and, as consequence, to 
increase the size of plaque [107]. However, recently it has been demonstrated that the PS 
exposition on cell membrane alone is not enough for an efficient efferocytosis. Phagocytes show 
significant redundancy in recognition strategies and are able to use many receptors at the same 
time [108]. This redundancy is important in order to activate a rapid clearance of apoptotic cells. 
Indeed, many phagocytes receptors take part in the elimination of apoptotic cells and the 
modulation of their expression is very important both in physiological and pathological 
conditions. Among these molecules, CD36 that recognizes thrombospondin [109], low density 
lipoprotein receptor-related protein 1 (LRP1) that interacts with PS-binding complement factor 
C1q to engulf apoptotic cells in association with its co-receptor (calreticulin) [110] and CD14, are 
the most important receptors involved in the efferocityc process. 
In particular, CD14 is a glycoprotein, initially identified as the receptor for LPS; it is a surface 
receptor specifically expressed from monocytes and macrophages that is found both anchored 
to the membrane and in soluble form into the cell cytoplasm. During the phagocytosis of 
pathogens, the binding between LPS and CD14 induces a pro-inflammatory response mediating 
by the nuclear factor NF-κB activation. In detail, CD14 recognize ICAM-3 that is greater express 
on the apoptotic cell membrane [111]. During the uptake of apoptotic cells, macrophages 
release anti-inflammatory mediators like IL-10 [112].  
The presence of specific receptors on the cellular membrane allows the recognition of apoptotic 
cells by phagocytes and to discriminate them from non apoptotic cells. The efficiency of 
efferocytic process depends by the balance between the quantity and the quality of positive 
signal “eat me” and negative “don’t eat me” expressed on apoptotic cell membrane. Among the 
“don’t eat me” signals expressed by non apoptotic cells CD31 (also known as platelet endothelial 
cell adhesion molecule (PECAM-1)) and CD47 (also known as integrin associated protein (IAP)) 
are the most studied. Notably, CD47 is recognized by signal regulatory protein α (SIRPα) and 
their interaction inhibits the efferocytic process; when CD47 expression is diminished during 
apoptotic process, the cell is cleared by efferocytosis [113].   
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The efferocytic process involves the protrusion of pseudopodia with the consequent 
cytoskeleton remodeling in the phagocytic cells when they bind apoptotic cells. These cytoplasm 
filled projections envelope the apoptotic cell, resulting in a phagosome with membranes in close 
contact with the ingest cells. The cell internalization activates the guanosine tryphosphate (GTP)-
ases, in particular the family of Rho GTP-ase. This family belongs to Ras superfamily that contain 
small proteins involved in cellular motility [114]. In particular, RhoA, Cdc42 and Rac play an 
important role in the efferocityc process. More in detail, RhoA inhibition induced the 
efferocytosis enhancement; in contrast, its activation is associated to a reducing efferocityc 
capability. The active form of RhoA cause an increase of the activity of Rho-associated coiled-
coil-containing protein kinase (ROCK), that in turn mediates the myosin phosphorylation of light 
chain promoting cellular contraction [115]. As a consequence, the cell is not able to radiate 
pseudopodia and to promote phagosome. Conversely, the RhoA activation seems to be 
necessary to promote the apoptotic cell digestion through the regulation of phagosome 
acidification [116]. After the apoptotic cell internalization, the phagosome sequentially expresses 
different proteins during its maturation, ultimately leading to fusion with an acidic lysosome 
structure, forming the phagolysosome. Inside phagolysosome, apoptotic cell is digested in his 
basal components such as peptides, sterols, nucleotides and lipids [117]. 
Other members of Ras family are involved in efferocytic process. In particular, Rac promotes 
efferocytosis and regulates cell internalization process through the activation of actin related 
protein (Arp) 2/3 complex that acts on actin polymerization. As a consequence, the cytoskeleton 
rearrangement promotes the pseudopodia radiation [118].  
Phagocytes can fit to this increased metabolic load by activating degradation and efflux 
pathways [119]. In effect, a number of recent studies have shown that engulfment of apoptotic 
cells itself engages multiple metabolic sensing pathways in macrophages to control phagocytosis 
and immune signaling [120, 121]. Among these, it has been demonstrated the role of 
mitochondrial uncoupling protein (UCP) 2. This protein uncouples oxidative phosphorylation and 
ATP synthesis, and reduces the potential of mitochondrial membrane inside the cells. It has been 
shown that an overexpression of this protein enhances the phagocytosis of apoptotic cells 
instead his downregulation inhibits this process, suggesting the role of mitochondria in the 
regulation of efferocytosis [122]. Furthermore, efferocytosis can modulates the cholesterol 
metabolism through the increase of ATP binding cassette (ABCA) 1 receptor expression. In 
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particular, it has been observed that cholesterol derived from apoptotic cell degradation 
becomes an integral part of cholesterol pool inside the phagocyte and, in response to the 
cholesterol loading, phagocyte potentiates the cholesterol efflux pathway [123].  
3.3.1 Role of efferocytosis in atherosclerotic disease 
Clearance of apoptotic cells by phagocytic cells plays a pivotal role in the resolution of 
inflammation. The phagocytic removal or apoptotic cells before they undergo lysis results in 
potent anti-inflammatory and immunosuppressive effects through the production of anti-
inflammatory cytokines such as TGF-β1 and PGE2 and the suppression of release of 
proinflammatory mediators, including IL-8, TNF-α and thromboxane A2 from activated 
macrophages [124]. Emerging evidence indicates that efferocytosis is impaired during 
atherogenesis and despite it is not yet understood why this process is dysfunctional, several 
studies have evidenced a dysregulation of “eat me” signals [125].  During atherosclerosis the 
apoptosis process is increased and several studies suggest that, in early lesions, the phagocytic 
clearance of apoptotic cells appears to be efficient. Apoptotic cells are rapidly removed through 
the efferocytic process performed by phagocytes present in the intimal layer, mainly M2 
macrophages [126]. Conversely, during atherogenesis phagocytes become less effective.  In 
advanced lesion, phagocytosis of apoptotic cells is severely compromised: this involves 
accumulation of apoptotic and necrotic macrophages and SMC that inhibit inflammation 
resolution and promote local necrosis and plaque instability [127]. Several factors may 
contribute to defective phagocytic clearance of apoptotic cells, leading to a secondary necrosis 
of these cells and a proinflammatory response. The possible mechanisms undrelying the 
reduction of the clearance of apoptotic cell were firstly suggested by Steinberg and Witztum. In 
particular, they observed that ox-LDLs compete with apoptotic bodies in the recognition by 
macrophages [128]. In fact, both ox-LDLs and apoptotic bodies exhibit oxidized lipid molecules or 
modified protein fractions which are recognized by macrophages [129]. Ox-LDL have 
immunogenic properties and the presence of auto-antibodies directed toward this modified 
lipoproteins have been identified in the atherosclerotic plaques [130]. These antibodies can also 
bind to apoptotic cells resulting in the inhibition of the phagocytosis by macrophages [131].  
Another factor that can contribute to the reduction of efferocytosis in the atherosclerotic plaque 
is the oxidative stress. PS as well as proteins or lipidic molecules present on membranes of 
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apoptotic cells or on macrophages are sensitive to the action of oxidizing agents. During the 
apoptotic process, PS may be oxidized and oxidized PS induces the secretion of pro-
inflammatory proteins such as MCP-1 and IL-8, which contribute to maintaining a chronic 
inflammatory state [132]. In addition, the ingestion by macrophages of particles that are difficult 
to degrade leads to a "stiffening" of macrophage cytoskeletal, with consequent inhibition of the 
morphological changes needed for the pseudopodia emission and a reduction in apoptotic 
bodies phagocytosis [133]. Accordingly, the reduced efferocytosis may depend on the 
suppression or decreased expression of molecules that mediate the interaction between 
apoptotic and phagocytic cells such as Gas6 and MFG-E8 [134].  
A reduction in clearance of apoptotic bodies promotes a number of processes that can 
contribute to plaque instability and the thrombus formation. Apoptotic cells that are not 
removed through the efferocytic process undergo a secondary necrosis that contributes to the 
growth of the necrotic core of the atheromasic plaque. The macrophage interaction with 
necrotic cells translates into an additional inflammatory response exacerbated by increased pro-
inflammatory cytokine secretion such as TNF-α and IL-12, and a reduced release of anti-
inflammatory proteins such as TGF- β and IL-10 [135]. All these mechanisms promote plaque 
development that may result in the plaque rupture. It has been observed that, in parallel with 
the accumulation of apoptotic cells, an increased expression and exposure of the tissue factor 
(TF) occur. TF is an activator of the extrinsic coagulation pathway, and its exposure, coming from 
the breakdown of an unstable plaque, lead to the formation of thrombi and, on consequence, to 
the cardiovascular event [136].  
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3.4 Transglutaminase 2 
The transglutaminases (TGs) are widely distributed in tissue mammals and include a peculiar 
group of enzymes that catalyze the post-translational modification of proteins. Thus far, nine 
distinct TG isoenzymes have been identified including the 7 isoforms, factor XIII (protein of 
coagulation cascade) and band 4.2 (erythrocyte protein enzymatically inactive). TG2, a 78-kDa 
calcium-dependent enzyme, is the most widely distributed member of the TG family and almost 
all cell types in the body express TG2 to varying extents. Inside the cell, TG2 is localized mainly in 
the cytoplasm but it is situated also on the cellular and mitochondrial membranes, in the nucleus 
and in the extracellular matrix [137]. TG2 is involved in several pathology such as celiac disease 
[138] and in neurodegenerative disorders including Alzheimer, Parkinson and Huntington 
diseases [139]. 
TG2 catalyze the thiol- and calcium dependent transamidation reactions that results in the 
crosslinking of proteins by epsilon-(gamma-glutamyl)lysine isopeptide bonds. In detail, the 
catalytic mechanism for crosslinking involves the thiol group from a Cys residue in the active site 
of TG2. The thiol group attacks the carboxamide of a glutamine residue on the surface of a 
protein or peptide substrate, releasing ammonia and producing a thioester intermediate. The 
thioester intermediate can then be attacked by the surface amine of a second substrate 
(typically from a lysine residue). The end product of the reaction is a stable isopeptide bond 
between the two substrates. Alternatively, the thioester intermediate can be hydrolyzed, 
resulting in the conversion of the glutamine residue to glutamic acid.  
Besides its classical transamidating/protein cross-linking activity, TG2 possesses several other 
enzymatic functions [137]. The first demonstration that TG2 can bind to and hydrolyze GTP came 
in 1987. In particular, the Gαh subunit of TG2 is able to activate phospholipase C (PLC)δ1 
through the interaction with α1-adrenergic [140], thromboxane A2 [141] , and oxytocin 
receptors [142]. Biochemical studies revealed that the transamidating and GTPase activities of 
this protein are mutually exclusive: Ca2+-bound TG2 has no GTPase activity, whereas GTP-bound 
TG2 does not exhibit TG activity [143].  The protein can also hydrolyze ATP, an activity which is 
believed to facilitate the promineralization capacity of TG2 in osteoblasts [144]. Moreover, TG2 
was found to display protein disulfide isomerase (PDI) activity in vitro [145] and in vivo [146]. 
More recently, and even more surprisingly, TG2 was reported to phosphorylate insulin-like 
growth factor-binding protein-3 (IGFBP-3) on the cell surface, and p53 tumor suppressor protein, 
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histones and retinoblastoma protein (Rb) in the nucleus, suggesting that it has an intrinsic 
serine/threonine protein kinase activity [147]. Finally, the vast array of TG2 functional activities 
in the cell is not limited to its enzymatic functions. TG2 was found engaged in the formation of 
noncovalent complexes with various cytoplasmic, cell surface, ECM, nuclear, and mitochondrial 
proteins [137]. This emerging adapter/scaffolding function of TG2, which is independent on its 
enzymatic activities, appears to regulate cell adhesion, ECM remodeling, survival, growth, 
migration, and differentiation due to modulation of several signaling pathways [148]. 
The multifunctionality of TG2 is dependent to his chemical structure. TG2 is composed by 4 
domains: 
 N-term domain: β-barrel structure that contains the binding site for fibronectin; 
 Catalytic domain: the binding site for the substrate and the catalytic triad involved in 
transamination reactions; 
 C-term domain: two β-barrel structures, once for GTP and adrenergic receptor α-1 
binding site and the other for PLC interaction. 
The functions of TG2 are regulated by calcium and GTP/GDP binding (Figure 3). Specifically, the 
binding with calcium induces the transaminase activity of TG2, instead, GTP binding inhibits this 
function. Depending on bound cofactor, TG2 takes different structural conformations that are 
been characterized by crystallography. In GTP bound form, the 2 C-term domains are 
overlapping so that block the substrate binding site inside catalytic core: in this case, TG2 is 
closed, compact and inactive. When TG2 binds calcium, the protein is in open conformation and 
the 2 C-term domains are far from active site. This is the active enzyme form since the catalytic 
site is accessible to the substrate [149].  
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Figure 3. Inactive and active form of TG2.  
In the image are represented the 4 domains: N-term in blue, catalytic site in green, the 2 C-term domain in red and yellow, respectively 
 
 
3.4.1 Role of TG2 in atherosclerotic disease 
Recent study have reported the involvement of TG2 in several cardiovascular diseases. In 
particular, it has been observed its role in glucose level regulation, platelet activity, hypertension 
development, atherosclerotic progression, in the modulation of vascular permeability and 
angiogenesis [150]. Cardiomyocytes, vascular cells and in particular macrophages express high 
levels of this protein [151] and recently several studies have demonstrated the role of TG2 in the 
macrophages efferocytic process [152, 153]. In particular, it has been demonstrated that the 
expression of this protein is fundamental for the formation of phagocyte portals [154]. 
Moreover, experiments conducted using TG2-/- mice have demonstrated that the absence of 
TG2 results in a significant reduction in the efferocitic capacity of macrophages and is associated 
with the development of splenomegaly and the production of autoantibodies. In particular, lack 
of protein seems to reduce in phagocyte capacity to internalize but not to bind the apoptotic cell 
and induces an increase in inflammatory response [155]. 
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3.5 Tissue Factor 
TF is the transmembrane receptor for factor VII/VIIa. The TF/FVIIa complex is the major cellular 
initiator of the blood coagulation cascade. TF is a membrane glycoprotein of 47-KDa belonging to 
the cytokine receptor protein superfamily and consists of three domains [156]: 
 extracellular domain, composed by of two fibronectin type III modules whose 
hydrophobic cores merge in the domain-domain interface and serves for factor FVIIa 
binding; 
 transmembrane domain; 
 cytosolic domain of 21 amino acids length inside the cell which is involved in the signaling 
function of TF. 
FVIIa is the main activator of the coagulation cascade since it leads to thrombin generation and, 
as a consequence, to fibrin deposition. In the coagulation extrinsic pathway, the formation of 
TF/FVIIa complex leads to the activation of factor X (FXa) that in turn promotes the formation of 
the complex composed by FXa and his cofactor FVa [157]. This complex is responsible for the 
conversion of prothrombin into thrombin, which cuts fibrinogen to form fibrin. Moreover, fibrin 
promote the FXIII activation that contribute to the clot stabilization through the crosslinking 
between fibrin molecules (Figure 4). 
 
 
Figure 4. Coagulation cascade 
 
Introduction 
35 
 
Because the contact of TF with blood is sufficient to initiate coagulation, TF expression in vessels 
is strictly regulate to preclude activation. In fact, TF is anatomically sequestered from the blood 
in physiological condition, being selectively expressed at sites isolated from plasma. In 
physiological condition, peripheral blood cells, endothelium and SMC do not have detectable TF 
levels. TF associated with vessel is predominately localized on fibroblasts of adventitia, pericytes 
and subendothelium cells [158, 159]. Moreover, TF is expressed in several organs such as brain, 
lung, heart, uterus, placenta, and testis, whereas low to undetectable levels are present in 
skeletal muscle, joints, and liver [160].   
Maintaining a nonthrombogenic vascular endothelial cell surface is achieved by the specific 
inhibitor for TF/VIIa, namely TF pathway inhibitor (TFPI). TFPI is synthesized by endothelium and 
remains bound to endothelial cells for inhibition of cell surface TF/VIIa in a Xa-dependent 
manner [161].  TFPI is a serin protease composed by a C-term domain, three repeated protease 
domains (Kunitz domains) and an N-term domain [162]. The mechanism of inhibition of the 
extrinsic coagulation cascade by TFPI is based on two different steps. First, TFPI binds FX through 
the Kunitz domain 2, inhibiting his activity. Second, the TFPI/FXa complex bind TF/FVIIa complex, 
forming TFPI-Xa-VIIa-TF quaternary complex so TF/FVIIa is not able to activate the coagulation 
cascade. The equilibrium between TF-FVIIa complex and TFPI is fundamental for maintaining 
haemostasis and alterations in this balance can lead to thrombosis or hemorrhagic events due to 
the prevalence of one or the other. In fact, it has been observed in mice embryos that the total 
absence of TF promote hemorrhagic death, instead TFPI lacking cause death for thrombosis 
[163].  
TF/FVIIa complex is involved not only in the coagulation cascade but also in different biological 
process. These functions are related to his similarity to class II cytokine receptors [164]. In 
particular, the binding through FVIIa and TF induced the activation of several mitogen-activated 
protein (MAP) kinase family members like p38, p42/p44 and c-Jun N-terminal kinase (JNK), [165] 
through G protein coupled protease-activated receptors (PARs), in particular PAR-2 [166]. Hence 
by activating different kinases involved in signal transduction, TF/FVIIa complex regulates the 
transcription of several genes involved in physiological and pathological processes such as cell 
migration, cell growth, or apoptosis.  
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3.5.1 Role of TF in atherosclerosis 
Many studies have demonstrated that TF in atherosclerotic plaques is the primary responsible 
for the thrombogenicity of the plaque and the primary cause of atherothrombosis [167]. Plaque 
disruption and subsequent arterial thrombosis is a sudden event in atherosclerosis resulting in 
acute vascular syndromes, such as myocardial infarction [168]. TF expression has been found to 
be correlated with the progression of human atherosclerotic lesions [169]. For instance, plaques 
from patients with unstable coronary syndromes and myocardial infarction showed higher TF 
activity in respect with those of patients with stable disease [170]. Within the plaque, not only 
macrophages, foam cells, and SMCs but also cell-derived micropartilces (MPs) and cellular debris 
derived from apoptotic foam cell in the necrotic core are TF sources [171]. TF expression is 
induced by several stimuli such as inflammatory cytokines (like TNF-α) and ox-LDLs. In particular, 
TNF-α promotes the expression of MCP-1, a chemokine involved in both the initiation and 
progression of atherosclerosis, that induces TF expression in both monocyte/macrophages and 
SMCs [172]. Moreover, ox-LDL is a potent activator of TF in monocytes [173], SMCs [174], and 
endothelial cells [175] through the binding to scavenger receptors and toll like receptors (TLRs), 
especially TRL4.  
During the atherosclerosis disease, TF not only triggers clotting but also may contribute to SMC 
migration, and cytokine and chemokine production. Indeed, TF contributes to SMC migration in 
vitro and in vivo [176], through the activation of PAR-2 signaling pathway [177]. Moreover, the 
TF activation of the PAR-2 results in the secretion of the inflammatory cytokine IL-6 and the 
chemokine IL-8 [178], and further leukocyte recruitment to the atherosclerotic lesion, thus 
enhancing the progression of atherosclerosis [179].  
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3.6 Oxidative stress 
Oxidative stress is caused by an imbalance between oxidant in particular ROS and antioxidant 
factors in favor of the oxidant ones. ROS include: free radicals, that contain one or more 
unpaired electrons, and non radicals species, formed when 2 free radicals shared their unpaired 
electrons. ROS can be classified on the basis of their origin: endogenous or exogenous. 
Endogenously, ROS are produced as a result of normal cell metabolism. The major ROS that are 
of physiological signiﬁcance are superoxide anion (O2-), hydrogen peroxide (H2O2) and the 
hydroxyl radical (•OH). In particular, O2- is formed by the addition of an electron to the 
molecular oxygen (O2) [180]. Many enzymatic reactions can produce ROS. In particular, nicotine 
adenine dinucleotide phosphate NADPH oxidase (NOX), xanthine oxidase and mitochondrial 
electron transport system are recognized sources of ROS in polymorphonuclear leukocytes, 
monocytes, and macrophages. Upon phagocytosis, these cells produce a burst of O2- as the 
bactericidal activity. O2- is converted into H2O2 by the action of superoxide dismutases (SODs). 
H2O2 is also produced by peroxisomes in metabolic reactions during consumption of O2. The 
most reactive ROS, •OH is produced by the degradation of H2O2 through Haber–Weiss and 
Fenton reactions [181].  
In addition to endogenous ROS, there are also exogenous sources of oxidant molecules that 
derive from cigarette smoke [182], ozone exposure, hyperoxia [183], ionizing radiations [184] 
and heavy metal ions [185].  
ROS can attack organic molecules, lipids, proteins and DNA resulting in marked modifications of 
these compounds. DNA damage, including degradation and modification of bases, single- or 
doublestranded DNA breaking, mutations, deletions or translocations, and cross-linking with 
proteins, may modulate numerous pathways through the activation of several stress-induced 
transcription factors and the production of pro- and anti-inflammatory cytokines. The extent of 
DNA damage determines cell fate: cell cycle arrest and DNA repair or the activation of apoptoitc 
pathways. A single double-strend break can cause apoptosis [186], inactivate key genes, or 
induce serious chromosomal aberration [187]. DNA damage leads to the loss of homeostasis and 
it is involved in several pathologies like tumors, neurodegenerative, autoimmune and 
cardiovascular diseases. Furthermore, oxidant molecules can induce lipid peroxidation. In the 
biological system, the most favorable substrate for peroxidation is represented by 
polyunsaturated fatty acid (PUFA), major constituents of cellular and subcellular membranes. In 
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particular, lipid peroxidation, taking an electron from PUFA, leads to structural disorganization of 
the membrane and deterioration of pores crossing the phospholipid bilayers [188]. This process 
modifies membrane properties such as membrane fluidity, alters the physiological functions of 
cell membranes, and contributes to cell membrane damage [189]. This cellular damage can have 
negative consequence for the organism, as modification of proteins, activation of kinases and 
inhibition of nuclear transcription factors.  
Moreover, ROS can promote also protein modification. The thiol group in proteins undergoes 
reversible and irreversible oxidation reactions, impacting on protein structure and function. In 
fact, oxidative stress may increase susceptibility to proteolysis by proteases degradation [190]. 
All together, these modifications can promote serious damage which may culminate in cell 
death. 
3.6.1 Antioxidant response 
Given the enormous range of reactivity of oxidant and given the different range of the targets, 
living cells can act different strategies to counteract oxidative damage. Cells activate several 
defense mechanisms in order to maintain tissue homeostasis, as the activation of superoxide 
dismutases (SOD), glutathione (GSH), catalases, paraoxonases (PON), heme-oxygenase-1, and 
nitric oxide (NO), which directly or indirectly counteract the oxidants.  Among them GSH and 
nuclear factor erythroid 2–related factor 2 (Nrf2)/ heme-oxygenase-1 (HO-1) are widely studied.  
3.6.1.1 GSH 
γ-L-glutamyl-L-cysteinyl-glycine, chiefly known as GSH, represent the major antioxidant system in 
the cells [191]. It belongs to thiols family [192] and is fundamental to maintain cellular 
homeostasis in order to protect cells by oxidative stress. GSH is generated in vivo by the 
consecutive action of two ATP-dependent enzymes, from the precursor aminoacids cysteine, 
glutamate and glycine. The first enzyme, glutamate–cysteine ligase (GCL), is the rate-limiting 
enzyme, while the second one, glutathione synthase is required for de novo GSH biosynthesis. 
The majority of cellular GSH (almost 90%) is in the cytosol, which also represents the main place 
for its synthesis; from cytosol, GSH is distributed into organelles such as mitochondria, nucleus 
and endoplasmic reticulum [193]. In contrast to GSH synthesis, which occurs intracellularly, GSH 
degradation occurs exclusively in the extracellular space, and, in particular, on the surface of 
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cells that express the γ-glutamyltransferase (GGT) [194]. GGT hydrolyzes GSH into glutamic acid 
and cysteinyl-glycine that is further hydrolyzed by cell surface dipeptidases and the resulting 
aminoacids taken up by cells for regeneration of intracellular GSH [195]. GSH levels depend not 
only by de novo synthesis but also by reduction of his oxidized form (GSSG). GSSG is 
characterized by a disulphide bond between two molecules of GSH that is efficiently reduced 
back to GSH by the NADPH-dependent catalysis of the flavoenzyme GSH reductase. The intra- 
and extra-cellular GSH levels are determined by the balance between its production, 
consumption, and transportation. 
Regarding its mechanism of action, it has been established that the thiol moiety of GSH is 
important in its antioxidant function, i.e. the direct scavenge of radical species. Indeed, the 
direct action of GSH towards oxidant and oxidized molecules happens thank to 
oxidation/reduction reaction of thiol group (-SH) of cysteine, that acts as reducing group. The 
redox state of GSH is due to an alternation between its reduced and oxidized form, and 
GSH/GSSG ratio is commonly used to define the redox state of a cellular system [196].  
GSH not only reacts directly with oxidants but it also acts as cosubstrate of enzymes like 
glutathione peroxidases (GSH-PXs) and GSH-s-transferases (GSTs). GSH-Pxs are a selenium-
dependent family of tetrameric enzymes that converts H2O2 into water or the peroxide lipids 
into water and their relative alcohols, with parallel GSH oxidation. Moreover, GSTs inactivate 
secondary metabolites such as unsaturated aldehydes, epoxides, and hydroperoxides. GSTs 
catalyze the conjugation between GSH and oxidized substrates, favoring their elimination by the 
organism.  
3.6.1.2 Nrf2/HO-1 pathway 
Nrf2 is a transcription factor sensitive to oxidative stress. It is the major regulator of the 
adaptative response to oxidative stress and induces the expression of several cytoprotective 
genes with antioxidant activities. Under basal unstressed conditions, Nrf2 is constitutively 
expressed and degraded directly by its cytoplasmic antagonist Kelch-like erythroid cell-derived 
protein with cap’n’collar homology-associated protein 1 (Keap1). Keap1 is a protein that 
promotes the ubiquitination and the proteosomic degradation of this transcription factor 
through the activation of Cil3/Rbx1 pathway. Instead, under oxidative stress stimulus, the 
complex Keap1/Nrf2 dissociate, and Nrf2 translocated into the nucleus. Here, associating with 
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antioxidant responsive element (ARE), Nrf2 promotes the transcription of proteins with 
antioxidant activity. Among them, HO-1 play a fundamental role in the antioxidant mechanism 
within the cell [197]. 
HO-1 is a microsomal enzyme that belong to oxidoreductases. Three isoforms of HO have been 
identified in mammals: HO-1, 2 and 3 [198, 199]. HO-1 is a 32 kDa protein and it is the inducible 
form of HO. Its expression occurs to several oxidant stimuli such as hypoxia, H2O2, heavy metal 
and pro-inflammatory cytokines like TNF-α or by heme catabolism [200, 201]. HO-2, a 36 kDa 
protein, is the constitutive form of HO an it is expressed in the majority of the cells and organs 
[202]. Finally, HO-3 (33 kDa) is the isoform lacking of catalytic activity [199]. Using O2 and NADPH 
as cofactor, HO-1 catalyzes the opening of heme ring promoting the production of carbon 
monoxide (CO), biliverdin and ferrous iron (Fe2+) [203]. Subsequently, biliverdin is reduced to 
bilirubin through biliverdin reductase, and iron is sequestered by ferritin [204]. These three 
molecules are involved in the cell protection [204]. CO has a double face: from one side, high 
levels of CO are lethal for the cells, in fact they can induce hypoxia; from the other side, several 
studies have demonstrated that low CO levels have positive effect on physiological cellular 
functions [205]. Bilirubin, like CO, at high level shows toxic effect, especially in babies [206], but 
in physiological condition have cytoprotective effects [207, 208]. Fe2+ is able to generate ROS 
[209], but his binding with ferritin neutralizes his capacity to participate in redox reactions [210].  
3.6.2 Oxidative stress and antioxidant response in atherosclerosis 
Among the ROS generators, NADPH oxidases (NOXs) and xanthine oxidase are the most 
important ones in atherosclerosis. Several NOX isoforms participate to atherosclerosis 
pathogenesis and development. NOX1 is upregulated in diabetes and its deletion is correlated 
with the reduction of atherosclerosis, similarly to what happens for NOX2 deletion. NOX5 is 
upregulated in diabetes, hypertension and in atherosclerotic lesions [211].  
Furthermore, macrophages and SMC express xanthine oxidase. In presence of oxidative stress 
stimulus, xanthine oxidase increased the expression of lipoxygenase (LOX)-1 and CD36 in these 
cell types and lead to the activation of inflammasome and the transformation of  macrophages 
and SMC into foam cells [212]. In addition to NOX and xanthine oxidase, myeloperoxidase is 
involved in atherosclerosis process. In fact, it has been observed that the levels of this enzyme 
are increased in patients with atherosclerotic coronary artery disease [213]. Myeloperoxidase 
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contribute to atherosclerosis pathogenesis through several pathways. It is known that this 
enzyme is responsible for the conversion of thiocyanate into hypothiocyanous acid [214] and this 
product can alter MAPK signaling and induce apoptosis in vascular cells. Moreover, 
hypothiocyanous acid promotes the oxidation of LDL, favoring the atherosclerosis process [215]. 
Using electronic paramagnetic resonance imaging for ROS visualization coupled to a non linear 
optical microscopy to study structured features it has been demonstrated that ROS are present 
at high concentration at lipid region of atherosclerotic plaque [216]. 
The cells within the plaque try to counteract the oxidative stress damage through the activation 
of several antioxidant systems. In particular, GSH and HO-1 have an important role during the 
atherosclerosis. Yang et al. have discovered that GSH regulates CD36 activity [217] and observed 
that macrophages treated with buthionine sulfoximine (BSO), a compound that inhibits GSH 
synthesis, show a decrease of intracellular GSH levels, had increased ROS production and CD36 
increased expression.  
Another mechanism of oxidative stress cellular response is represented by HO-1. Several studies 
have demonstrated an atheroprotective role of HO-1. In vascular cells, HO-1 is induced by ox-LDL 
[218]. It has been observed that in macrophages, SMC and endothelial cells HO-1 expression is 
greater after exposition to ox-LDL, instead his levels are reduced in the presence of native LDL 
[219, 220]. HO-1 plays a protective role in atherosclerotic lesions as high HO-1 levels diminish 
the production of pro-inflammatory mediators and contrasts the inactivation of eNOS due to the 
presence of ox-LDL and TNF-α [221]. Moreover, it inhibits the expression of TNF-α and IL-1β and, 
in parallel, increases IL-10 levels both in macrophages and in endothelial cells by the production 
of CO [222]. Finally, the induction of HO-1 and CO downregulates the expression of endothelin-1, 
PDGF and VEGF that leads to the reduction of SMC proliferation [223]. 
it has been shown that leukocytes from CAD patients express HO-1 and its levels are correlated 
with the severity of disease [224]. Moreover, it has been also observed that vulnerable plaque 
present higher HO-1 levels in respect to stable ones [225].  
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3.7 Fatty Acids 
Fatty acids are the most important components of all lipid classes and they are widely diffused in 
all living organisms. In humans, they are present in high concentration in cell membranes, in the 
adipose tissue (in the form of triglycerides) and in the myelin sheath. These molecules are 
carboxylic acids with a aliphatic chain composed from 4 to 36 carbon atoms. They can be 
classified on the basis of the length of aliphatic chain into:  
 short-chain fatty acids (SCFA) containing of 1 to 6 carbons; 
 medium-chain fatty acids (MCFA) with aliphatic tails ranging from 6 to 14 carbons; 
 long-chain fatty acids (LCFA) with aliphatic tails of 16 to 36 carbons. 
Fatty acids are also classified according to the presence of double bonds in the aliphatic chains: 
saturated fatty acids, with no double bonds, and unsaturated fatty acids that are characterized 
by the presence of one (monounsaturated) or more double bonds (polyunsaturated). The main 
saturated fatty acids present in biological systems are palmitic acid (C16:0) and stearic acid 
(C18:0) (Table 1A). 
The nomenclature of fatty acids is very complex and the position of double bonds can be 
described by indicating the number of carbon atoms starting from COOH- end (C-n notation) or –
CH3- end (ω-n notation). The double bond position in C-n notation is also indicated by Δn, where 
n is the number of carbon atom in which the double bond is localized. For example, in a 18 
carbons fatty acid, a double bond between C-12 (or ω-7) and C-13 (or ω-6) is reported either as 
Δ12 if counted from the –COOH end, or as ω-6 (or omega-6) if counting from the –CH3 end. 
 
 
Fatty acid Chemical structure C:D 
Lauric acid CH3(CH2)10COOH 12:0 
Myristic acid CH3(CH2)12COOH 14:0 
Palmitic acid CH3(CH2)14COOH 16:0 
Stearic acid CH3(CH2)16COOH 18:0 
Arachidic acid CH3(CH2)18COOH 20:0 
Behenic acid CH3(CH2)20COOH 22:0 
Lignoceric acid CH3(CH2)22COOH 24:0 
Cerotic acid CH3(CH2)24COOH 26:0 
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Fatty acid Chemical structure Δx C:D 
Palmitoleic acid CH3(CH2)5CH=CH(CH2)7COOH cis-Δ9 16:1 
Oleic acid CH3(CH2)7CH=CH(CH2)7COOH cis-Δ9 18:1 
Linoleic acid CH3(CH2)4CH=CHCH2CH=CH(CH2)7COOH cis,cis-Δ9,Δ12 18:2 
Linoelaidic acid CH3(CH2)4CH=CHCH2CH=CH(CH2)7COOH trans,trans-Δ9,Δ12 18:2 
α-Linolenic acid CH3CH2CH=CHCH2CH=CHCH2CH=CH(CH2)7COOH cis,cis,cis-Δ9,Δ12,Δ15 18:3 
Arachidonic acid CH3(CH2)4CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)3COOH cis,cis,cis,cis-Δ5Δ8,Δ11,Δ14 20:4 
Eicosapentaenoic acid 
(EPA) 
CH3CH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)3
COOH 
cis,cis,cis,cis,cis-
Δ5,Δ8,Δ11,Δ14,Δ17 
20:5 
Erucic acid CH3(CH2)7CH=CH(CH2)11COOH cis-Δ13 22:1 
Docosahexaenoic acid 
(DHA) 
CH3CH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2C
H=CH(CH2)2COOH 
cis,cis,cis,cis,cis,cis-
Δ4,Δ7,Δ10,Δ13,Δ16,Δ19 
22:6 
 
Table 1. Examples of saturated (A) and unsaturated (B) fatty acids 
 
Unsaturated fatty acids are also classified by the position of the two hydrogen atoms adjacent 
the double bond. In detail, when they are present on the same side of the chain, they have a cis 
configuration,which causes the chain to bend. In fact, when a chain has many cis bonds, it 
becomes quite curved. When the adjacent two hydrogen atoms lie on opposite sides of the 
chain there is trans configuration (Table x B). As a result, they do not cause the chain to bend 
much, and their shape is similar to straight saturated fatty acids. The differences between 
saturated and unsaturated fatty acids, as well in geometry between the various types of 
unsaturated fatty acids, play an important role in biological processes, in the construction of 
biological structures (such as cell membranes) and in cell functions. 
3.7.1 Biosynthesis of fatty acids 
Fatty acids biosynthesis occurs predominantly in the liver, adipose tissue, kidneys, brain, lungs 
and in the mammary glands. In detail, fatty acids are synthesized in the cytoplasm of the cells 
from acetyl-CoA. Acetyl-CoA is obtained in mitochondria from oxidative decarboxylation of 
pyruvate catalyzed by pyruvate dehydrogenase or from fatty acids β-oxidation. Acetyl CoA needs 
to be transported into cytosol and this cannot occur directly. To obtain cytosolic acetyl-CoA, the 
citrate (produced by the condensation of acetyl-CoA with oxaloacetate) is removed from the 
Krebs cycle and carried across the inner mitochondrial membrane into the cytosol. At this level, 
it is cleaved by ATP citrate lyase into acetyl-CoA and oxaloacetate. The oxaloacetate returns to 
the mitochondrion as malate.  For each acetyl-CoA molecule that is transported in the cytosol, it 
is produced a molecule of nicotinamide adenine dinucleotide phosphate (NADPH), a co-factor 
B 
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essential in fatty acids biosynthesis (Figure 5). The other co-factors fundamental for the process 
are ATP, necessary for carbon dioxide (CO2) binding forming malonyl-CoA, manganese (Mn++), 
biotin and bicarbonate (HCO3-) as a source of CO2. 
 
 
Figure 5. Scheme of the transfer of acetyl CoA from mitochondrion to cytosol 
 
The standard way for cells to synthesize fatty acids is through the fatty acid synthesis cycle. This 
cycle is composed by seven reactions catalyzed by seven enzymes: acyl-CoA carboxylase (ACC), 
acyltransferase, ketoacyl synthase, ketoacyl reductase, hydroxyacyl dehydratase, enoyl 
reductase, and thioesterase (Figure 6).  
 
 
Figure 6. Fatty acids biosynthesis 
ACC is a biotin dependent enzyme that controls all the biosynthetic pathway. It catalyzes 
carboxylation of cytosolic acetyl-CoA to produce malonyl-CoA, using ATP and HCO3- as co-factors. 
With ketoacyl synthase and acyltransferase catalysis, malonyl-CoA is added to an acyl chain, 
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usually activated with acyl carrier protein, making an acyl chain two methylene groups longer. 
Further reduction, dehydration, and reduction with ketoacyl synthase, hydroxyacyl dehydratase, 
and enoyl reductase catalysis, respectively, leads to a saturated and unhydroxylated acyl chain 
activated with acyl carrier protein. When the chain is of appropriate length, it is attacked by 
thioesterase to release acyl carrier protein, yielding the finished fatty acid. All these enzymes 
together are called elongases and have been given the designation Elovl for elongation of very 
long fatty acids (Elovl 1–7). 
Palmitic acid (C16:0) is the longer fatty acid synthetized by the cycle and can be the precursor of 
LCFA. This fatty acid can be elongated to form stearic acid (C18:0) or a longer fatty acids through 
subsequently addition of acetylic units.  This reaction is catalyzed by elongation complex present 
in the endoplasmic reticulum that lengthens the fatty acid chain of two carbons, donate by 
malonyl-CoA, leading to stearyl-CoA formation. The stearyl-CoA will be reduced, dehydratated 
and re-reduced to generate stearoyl-CoA, a 18 carbon atoms saturated product.  
Fatty acid desaturases are enzymes that removes two hydrogen atoms from a fatty acid, creating 
a carbon/carbon double bond. Four desaturases occur in humans: Δ9, Δ6, Δ5, and Δ4 desaturases. 
Δ9 desaturase, also known as stearoyl-CoA desaturase1 (SCD1) is a microsomal enzyme which 
facilitate the formation of monounsaturated fatty acids (MUFAs) from saturated fatty acid 
precursors. More specifically, SCD1 converts palmitoyl-CoA and stearoyl-CoA to palmitoleoyl-
CoA and oleoyl-CoA, respectively [226]. Δ6 and Δ5 desaturases are required for the synthesis of 
highly unsaturated fatty acids (HUFAs) such as EPA and DHA (synthesized from α-linolenic acid), 
and arachidonic acid (synthesized from linoleic acid) [227]. This is a multi-stage process requiring 
successive actions by elongase and desaturase enzymes (Figure 7). 
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Figure 7. MUFAs and HUFA synthesis 
The precursors of HUFAs, linoleic acid and α-linolenic acid are essential fatty acids as they cannot 
be synthesized in the body and have to be intaken with food. They are characterized by the 
presence of the double bond in a specific position: α-linolenic acid is a (ω-3) fatty acid; while 
linoleic acid is a (ω-6).  
The cell membrane fatty acids composition is fundamental in both physiological and pathological 
state. In particular, the balance between unsaturated and saturated fatty acids play a 
fundamental role in several cell types such as lymphocytes, neutrophils and macrophages. 
3.7.2 Macrophages fatty acid compositions 
Calder and his group have observed that the main fatty acids present in the neutral lipid fraction 
(esters of fatty acids and alcohols, for example triacylglycerols) of macrophages were palmitate 
and stearate that reflected 40% and 15 % respectively of the total fatty acids. They also observed 
that the neutral lipid of macrophages contained approximately two fold the saturated fatty acids 
than the unsaturated ones. Moreover, they noticed that the principal MUFA acid was oleate and 
only 10% of the fatty acids were PUFA. They have also seen that in the phospholipid fraction of 
macrophages, the main fatty acids were palmitate and stearate and that they each comprised 
over 20% of the total fatty acids. Finally, they observed that the content of polyunsaturated fatty 
acid was higher in the phospholipid fraction compared with the neutral lipid fraction. In 
particular, they showed that PUFA were the 27 %, and among them, arachidonate was major 
portion, representing 18 % of the total fatty acids [228]. 
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The fatty acid composition of the membrane influences membrane fluidity that in turn modify 
receptor function and/or the activity of signal transduction mechanisms [229]. Interactions of 
macrophages with the extracellular matrix and with other cells are important in several 
functions such as tissue repair, inflammation, immunity and atherosclerosis [19, 230]. Many of 
these interactions, including binding to endothelial cells, migration into tissues, interaction with 
T- lymphocytes, uptake of lipoproteins depend upon specific plasma membrane receptors [231]. 
In particular, the changing in fatty acid composition of macrophages can influence their ability to 
adhere to endothelium. In fact, it has been demonstrated that adhesion of macrophages that 
were enriched with saturated fatty acids was greater than that of those cells enriched with 
unsaturated fatty acids [228]. Moreover, it has been observed that the phagocytosis processes is 
influenced by membrane structure, in particular by the fluidity of the membrane; the latter is 
influenced markedly by the lipid composition [232]. In particular, an increase in membrane 
unsaturated fatty acids content, that is correlated to a high membrane fluidity, is associated with 
an increase in phagocytosis rate [233].
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Oxidative stress and inflammation are primary drivers of the pathological changes during 
atherosclerosis, from the formation of lipid-laden foam cells within the intima to the necrotic 
lipid core of unstable plaque. In the vascular wall, many cell types have been shown to be able to 
produce reactive oxidant species (ROS). Among these, monocytes/macrophages are a significant 
source of ROS in atherosclerotic lesions. Superoxide anion (O2-) participates in atherogenesis 
through the formation of oxidized lipids, particularly in low density lipoproteins. Moreover, it 
may contribute to the pathogenesis of atherosclerosis through the alteration of different cell 
functions, including adhesion, proliferation, and motility. High levels of oxidative stress induce 
also an adaptive endogenous defence mechanism that mediates the activation of antioxidant 
responses. Among them, nuclear factor erythroid 2–related factor 2 (Nrf2)/ heme-oxygenase-1 
(HO-1) pathway is one of the most studied. In presence of oxidative stress, Nrf2 induces the 
transcription of HO-1 that mediates the antioxidant response. It has been shown that HO-1 
protein levels correlated with plaque instability and it is expressed in macrophages of human 
atherosclerotic lesion.  
Macrophages are hallmarked by morpho-phenotypic heterogeneity and distinct subpopulations, 
with pro-inflammatory or reparative characteristics, have been identified in experimental animal 
models and in human atherosclerotic lesions. Given the contrasting properties pro- or anti-
inflammatory of macrophages, the nature of macrophage phenotype may exert harmful or 
beneficial functions in progression and/or destabilization of the atherosclerotic plaque. Recently, 
we have shown in healthy subjects that human monocytes spontaneously differentiated into 
macrophages (MDMs) display two dominant morphotypes co-existing in the same culture, 
namely round MDMs with functional traits reminiscent of a non-inflammatory and reparative 
phenotype, and spindle MDMs exhibiting a pro-inflammatory profile. However, no information is 
available concerning the behaviour of MDMs in patients with coronary artery disease (CAD).  
The aim of the study was to assess the biochemical and functional profile of spontaneously 
differentiated MDMs obtained from CAD patients. We assessed also the oxidative stress levels 
and the Nrf-2/HO-1 response in MDMs of our study population. Moreover, we investigated the 
relationship between the characteristics observed in MDMs in vitro with plaque features 
observed in vivo by optical coherence tomography (OCT). 
The combination between these data could provide a unique signature for identification of 
atherosclerotic process prone to coronary event. 
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5.1 Patient population 
Ninety consecutive CAD patients undergoing coronary angiography, due to stable angina (SA) or 
acute coronary syndrome (ACS), as their first manifestation of ischemic heart disease, were 
included in the study between October 2014 and May 2017. Patients enrollment was performed 
at Centro Cardiologico Monzino, Milan, Italy. SA was defined as angina on effort with a stable 
pattern of symptoms for at least the last six months prior to admission; ACS diagnosis 
encompassed patients presenting with non-ST-elevation (NSTEMI) or ST-elevation-acute 
myocardial infarction (STEMI). NSTEMI was defined as chest pain at rest in the last 48 h 
preceding the admission associated with evidence of transient ST-segment depression on 12-
lead electrocardiogram and normal (unstable angina) or elevated (NSTEMI) serum troponin I 
levels; while the diagnosis of STEMI was based on typical symptoms lasting more than 30 
minutes and new ST-segment elevation at the J point in ≥2 contiguous leads (≥0.2 mV in V1 
through V3 and ≥0.1 mV in other leads). All included NSTEMI patients underwent coronary 
angiography within 24 hours from admission, while all enrolled STEMI patients underwent 
primary percutaneous coronary intervention within 12 hours of symptom onset. In 50 out of the 
90 CAD patients, OCT assessment was also performed, aiming at investigating the association 
between the MDMs morpho-phenotype and coronary plaque morphology. The exclusion criteria 
were: previous history of CAD (any previous diagnosis of stable or unstable coronary syndrome); 
severe chronic heart failure (NYHA class III-IV), severe heart valve disease, acute and chronic 
infections, liver diseases, neoplasia, evidence of immunologic disorders, use of anti-
inflammatory or immunosuppressive drugs and recent (<3 months) surgical procedures or 
trauma. In all patients cardiovascular risk factors were examined, including family history of early 
CAD (first degree relative with a history of myocardial infarction <60 years), diabetes (fasting 
blood glucose >126 mg/dl or treated diabetes), hypercholesterolemia (total cholesterol >200 
mg/dl or treated hypercholesterolemia), smoking, and hypertension (systolic blood pressure 
>140mmHg and/or diastolic blood pressure >90mmHg or treated hypertension). Body Mass 
Index (BMI) and laboratory data, including hemochrome, serum glucose, serum creatinine, lipid 
profile, and high-sensitivity (hs)-CRP were recorded. Medications taken on admission were also 
recorded. Twenty-five healthy volunteers, with neither history of CAD, nor cardiovascular risk 
factors, nor inflammatory disorders, and specifically not taking any cardiovascular therapy, 
served as control group. All patients gave their written informed consent for participation in the 
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study; all volunteers provided written informed consent at the time of enrollment, as well. The 
ethics committee approved the study protocol, and the study was performed according to the 
Declaration of Helsinki.  
5.2 Blood collection  
All patients underwent venous blood sampling for biological measurements within 12 hours 
following coronary angiography. Venous blood samples were drawn from the antecubital vein of 
healthy subjects and CAD patients into tubes containing EDTA (9.3 mM; Vacutainer Systems, 
Becton Dickinson, Franklin Lakes, NJ, USA). The laboratory data were available for all enrolled 
subjects.  
5.3 Methodologies 
5.3.1 Monocyte isolation and culture  
Monocytes were isolated from venous blood of all enrolled subjects. Mononuclear cells were 
isolated by Ficoll-Paque Plus (GE Healthcare, Milan, Italy) density centrifugation at 450 g for 20 
min at room temperature (RT). To remove platelet contamination, lymphocyte/monocyte-rich 
layer was washed with PBS containing 5mM ethylenediaminetetraacetic acid (EDTA) and 
suspended in RPMI 1640 (Lonza Milano S.r.l, Bergamo, Italy) supplemented with 2mM L-
glutamine (Lonza), 100 U/ml penicillin, 100 µg/ml streptomycin (Lonza), and 10% autologous 
serum freshly obtained from blood clotted for 2 h at 37°C. Mononuclear cells were then plated 
(2x106/ml) in 35mm well plates (PrimariaTM, Falcon, Sacco S.r.l, Como, Italy) and kept at 37°C 
(5% CO2). After 90 min, non-adherent cells were removed and those adherent were cultured 
over 7 days at 37°C (5% CO2) in Medium 199 (Lonza) supplemented with 2mM L-glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, and 10% autologous serum. Medium was not replaced 
throughout the culture period. The endotoxin levels of all culture materials and reagents used 
was measured by the Limulus amoebocyte lysate assay (Lonza). To avoid MDM activation, only 
preparations free of endotoxin or containing <30 pg/ml were used. MDM morphology was 
examined by phase contrast microscopy (AxioVert 200M, Zeiss, Milan, Italy) at 20× or 40× 
magnification. MDM were defined spindle/elongated when a length >70µm and a width <30µm 
were detected; while round MDMs were defined when width and length >35-40µm were found. 
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Cells, whose morphology and dimension did not satisfy the above criteria, were defined as 
undefined MDMs. Both MDM morphotypes, round and spindle, stained positively for the pan-
leukocyte antigen CD45 and for the specific macrophage marker CD68. 
5.3.2 Western Blot 
Cells were washed twice with PBS and lysated in a buffer (Tris 20 mM, SDS 4% and glycerol 20%) 
containing protease inhibitors (ortovanadate 1mM, NaF 1mM, leupeptin 1µg/mL, benzamidine 
1mM, EDTA 1mM, trypsin inhibitors 10 µg/mL, pefabloc 0.5 mM, DTT 0.5 mM) . Protein 
concentration was determined by the micro-BCA assay (Thermo Fisher, San Jose, CA, USA). Equal 
amounts of lysates (40 µg of protein) were subjected to SDS–polyacrylamide gel electrophoresis 
on 7% gels running over night and were transferred onto nitrocellulose membrane by a semidry 
transfer unit (Hoefer Scientific Instruments) for 2 hours at room temperature. The membrane 
was saturated in a solution of T-TBS containing 5% of BSA. After washing, the blots were 
incubated with the appropriate primary antibodies. After wash with T-TBS, horseradish 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (Jackson ImmunoResearch 
Labs Inc., Li StarFISH, Milan, Italy) was used at 1:5000 dilution and incubate for 1 hour and 30 
minute at RT. β-Actin (1:10000) was used as internal standard for control of protein load.  
5.3.3 Immunofluorescence 
Adhered MDMs were washed twice with PBS and fixed with 2% para-formaldehyde (PFA) (Merck 
& Co., USA) for 15 min at RT. Plates, washed twice with PBS, were air dried. After, was added 5% 
bovine serum albumin (BSA) (Sigma-Aldrich, Milan, Italy) solution containing 0.1% saponin (Carlo 
Erba, Milan, Italy) for 30 min at RT due to blocked non-specific reactive sites. MDMs were 
incubated overnight at 4°C with the appropriate primary antibody. Detection was performed 
with appropriate Alexa Fluor 488 (green emission) (10 µg/ml, 60 min, RT) (Life Technologies 
Italia, Monza, Italy). Nuclei were visualized by Hoechst 33258 (Sigma-Aldrich) 1:10000. Negative 
control experiments were performed by omitting the primary antibodies. 
5.3.3.1 Quantitative image analysis 
Fluorescent images were captured on an AxioObserver.Z1 microscope connected to a digital 
camera using the image processor AxioVision 4.7 (Zeiss, Milan, Italy). Fluorescence intensity 
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(densitometric sum of gray) was quantified, as an index of the amount of the protein 
investigated. Data are expressed as mean±S.D. of fluorescence intensity/µm2 for each MDM 
morphotype, subtracted of the negative control value obtained in the absence of primary 
antibody. Multiple fields of view (at least three fields, 400× magnification) were captured for 
each culture.  
5.3.4 Apoptosis of Jurkat-T cells 
Jurkat T-cell line, clone E6-1 (ATCC), was purchased from LGC Standards S.r.l., Milan, Italy, and 
cultured in RPMI 1640 supplemented with 10% fetal calf serum (Lonza) and 26mM HEPES. Early 
and late apoptotic Jurkat cells were obtained upon incubation (4x106 cells/ml) in serum-free 
RPMI 1640 with 10 µM etoposide (Sigma–Aldrich) for 2 h. The extent of apoptosis was evaluated 
by flow cytometry using annexin V PE (BD Biosciences, Oxford, UK), according to the 
manufacturer’s instructions. A total of 20000/sample events were acquired. Apoptosis was also 
assessed in PFA-fixed Jurkat T-cells by the evaluation of chromatin condensation (Hoechst 33258 
stain, Sigma–Aldrich).  
5.3.5 Efferocytosis assay 
Jurkat T-cells were stained with 5µM carboxyfluorescein diacetate succinimidyl ester (CFSE, Life 
Technologies) for 30 min at 37°C before the induction of apoptosis. CSFE-labeled apoptotic cells 
(1x106 cells/ml) were co-cultured with MDMs (2:1 ratio) for 30 min. Non-ingested cells were 
removed. Adherent MDMs were detached with trypsin, incubated with 10 µl of APC-conjugated 
monoclonal mouse anti-human CD14 antibody (BD Biosciences), or 10 µl of isotype-matched 
irrelevant antibody, for 15 min at RT, and analyzed by flow cytometry. MDMs were gated on the 
basis of forward and side scatter properties. 10000 events were acquired, and the data were 
analyzed using CellQuest software (BD Biosciences).  
5.3.6 Thrombin generation measurement  
Adherent MDMs were lysed with 15 mM octyl-𝛽-D-glycopiranoside (Sigma Aldrich). 1 μg cell 
lysed (20 μl) were mixed with 10 μl of HEPES buffered- Saline and 20 μl of platelet-poor plasma. 
Thrombin generation was triggered by the addition of fluorogenic substrate Z-Gly-Gly-Arg-AMC 
(Stago Italia S.R.L. Unipersonale, Milan, Italy) in the presence of CaCl2 and measured for 60 min 
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using the Calibrated Automated Thrombogram® assay (Thrombinoscope BV, Maastricht, the 
Netherlands). The lag-time, peak of thrombin generation, endogenous thrombin potential (ETP), 
and velocity index of propagation phase (VelIndex) were calculated using Thrombinoscope 
software (Thrombinoscope BV). 
5.3.7 Enzyme activity assay  
Adherent MDMs were washed twice with PBS and 1 ml of fresh RPMI 1640 medium (Lonza) 
containing 0.2% fatty acid free albumin (Sigma-Aldrich) was added. After overnight incubation 
supernatant was collected, centrifuged at 200 g for 5 min at 4°C and the activity of matrix 
metalloproteinase (MMP)-9 secreted by MDMs was evaluated using colorimetric analysis using 
BiotrakTM activity assay system (Amersham, GE Healthcare, Milan, Italy). In brief, standards and 
samples (100 µl) were incubated in microtitre wells precoated with anti-MMP-9 antibody over 
night at 4°C. The wells were washed 4 times with wash buffer (Amersham, GE Healthcare, Milan, 
Italy), and 50 µl of p-Aminophenylmercuric Acetate (APMA) (Amersham, GE Healthcare) was 
added. The plate was incubated for 1.5 hours at 37 °C. At the end of incubation, 50 µl of 
detection reagent (Amersham, GE Healthcare) was added.  The plate was shaked for 20 second 
and it was read at 405 nm in a microplate spectrophotometer Mithras LB 940 (Berthold Italia, 
Milano, Italy). The concentration of active MMP-9 in a sample was determined by interpolation 
from a standard curve.  
5.3.8 Mass spectrometry analysis 
5.3.8.1 GSH/GSSG determination 
The determination of GSH and GSSG was performed using a LC-MS/MS method [234]. In detail, 
macrophages were washed twice with PBS and detached from plate using a cell scarper. The 
cells were collected into a tube and centrifuge at 100 g for 10 min. After centrifugation, the 
supernatant was discarded and the pellet was suspended in a solution of PBS containing 0.1µg of 
leupeptin, 0.2 M benzamidine and 1µg of trypsin inhibitor (Sigma-Aldrich) and mixed with 10% 
trichloroacetic acid (TCA) containing 1 mM EDTA solution in a 1:1 (v/v) ratio. After centrifugation 
at 13100 g for 10 min at RT, the supernatant was diluted 1:20 with 0.1% formic acid. Liquid 
chromatography was performed using an Accela HPLC pump system (Thermo Fisher Scientific). 
The separation of analytes was conducted on a Luna analytical PFP column (100x2.0 mm, particle 
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size 3 µm) maintained at 35°C. The mobile phase was composed by two solvents: solvent A 
(ammonium formate 0.75 mM adjusted to pH 3.5 with formic acid) and solvent B (methanol). 
Separation was performed under isocratic conditions with 99% mobile phase A at flow rate of 
200 μl/min for a total run time of 10 min per sample. Mass spectrometric analysis was 
performed using a TSQ Quantum Access (Thermo Fisher) triple quadrupole mass spectrometer 
coupled with electrospray ionization (ESI) operated in positive mode. The selected reaction-
monitoring (SRM) was performed by monitoring the transitions m/z 308.1→ m/z 76.2 + 84.2 + 
161.9 (GSH)  and m/z 613.2 → m/z 230.5 + 234.6 + 354.8 (GSSG). The operating conditions for 
MS analysis were as follows: spray voltage, 2500 V; capillary temperature and voltage, 280 °C 
and 35 V, respectively; sheat gas and auxiliary gas flow, 30 and 5 arbitrary units, respectively; 
tube lens offset, 84 V for GSH and 115 V for GSSG. The mass spectrometer was employed in 
MS/MS mode using argon as collision gas. The method validation was based on U.S. Food and 
Drug Administration [235]. Data acquisition and analysis were performed with 
Xcalibur®software, version 2.0 (Thermo Fisher). 
5.3.8.2 Total and free fatty acid composition assessment 
The determination of the total and free fatty acid composition was performed using a LC-MS 
method [236]. In detail, macrophages were washed twice with PBS and detached from plate 
using a cell scarper. The cells were collected into a tube and centrifuge at 100 g for 10 min. After 
centrifugation, the supernatant was discard and the pellet was conserved at -80°C until the 
analysis. For the analysis, pellets were suspended with 25µl of standard mix, composed by 
linoleic acid- 13C18 (Sigma-Aldrich) 2 ng/µl and palmitic acid- 13C16 (Sigma-Aldrich) 2 ng/µl in 
methanol, and with a 1 ml of methanol/acetonitrile (50:50 v/v). After centrifugation at 13100 g 
for 5 min at 4°, the supernatant was divided into two aliquots for the analysis of total and free 
fatty acid composition, respectively.  
For total fatty acid quantification, in each sample were added 2.5 ml of methanol/ chloroform 
(50:50 v/v), 1.25 ml of chloride acid 1M and 1.25 ml of methanol. The samples were kept in 
agitation for 1 hour and 30 minutes and after that, 1.25 ml of water and 1.25 ml of chloroform 
were added. Samples were shaken vigorously; the organic phase was collected and dried under 
nitrogen flow. Dry pellets were suspended in 200 µl of methanol/water (50:50 v/v) and 100 µl 
were transferred into a 96 well plate and placed in an auto-sampler for LC-MS analysis.  
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For free fatty acid quantification, the supernatants were dried under nitrogen flow and 
suspended in 200 µl of methanol/water (50:50 v/v). 100 µl of these suspensions were 
transferred into a 96 well plate and placed in an auto-sampler for LC–MS analysis. 
Liquid chromatography was performed using Agilent 1200 binary Pump (Agilent Technologies, 
USA). The separation of analytes was conduct on a Hypersil GOLD C8 column (100x3.0 mm, 
particle size 3 μm) maintained at 40 °C. The mobile phase was composed by two solvents: 
solvent A (isopropylethylamine10 mM and acetic acid15 mM) and solvent B (methanol). 
Separation was performed under gradient condition as follows: T 0: 20% A, T 20: 1% A, T 25: 1% 
A, T 25.1: 20% A, T 30: 20% A at a flow rate 500 µl/min for a total run time of  30 min per sample. 
Mass spectrometric analysis was performed using an API 4000 (AB Sciex, USA) triple quadrupole 
mass spectrometer coupled with electrospray ionization (ESI) operated in negative ion mode. 
The selected ion-monitoring (SIM) was performed by monitoring the ion m/z 279.23 (linoleic 
acid), m/z 277.22 (g-linolenic acid), m/z 303.23 (arachidonic acid), m/z 327.23 (docosahexaenoic 
acid), m/z 283.26 (stearic acid), m/z 311.30 (arachic acid), m/z 339.33 (behenic acid), m/z 281.25 
(oleic acid), m/z 255.23 (palmitic acid), m/z 253.22 (palmitoleic acid), m/z 301.22 
(eicosapentaenoic acid),  m/z 365.34 (nevronic acid), m/z 337.31 (erucic acid), m/z 367.36 
(lignoceric acid), m/z 269.25 (megaric acid), m/z 297.30 (linoleic acid- 13C18) and m/z 256.41 
(palmitic acid- 13C16). 
The operating condition for MS analysis were as follow: IonSpray voltage (IS), 4500 V; 
temperature (TEM), 500 °C; Ion Source Gas 1 (GS1) and Ion Source Gas 2 (GS2), 50 and 55 
arbitrary units, respectively; Curtain Gas (CUR), 40 L/min; Collision Gas (CUR), 3 L/min. 
Data acquisition and analysis were performed with MultiQuant™ software, version 3.0 (AB 
Sciex). 
 
5.3.9 OCT analysis 
5.3.9.1 OCT image analysis 
Culprit lesion in acute myocardial infarct (AMI) patients was identified by means of angiography, 
electrocardiographic T-wave or ST-segment alterations, and/or regional wall motion 
abnormalities on echocardiographic assessment. In SA patients, OCT analysis was performed at 
the minimal lumen area (MLA) site. Frequency domain OCT (FD-OCT) images were acquired by a 
commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) 
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connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical), which was 
advanced to the culprit lesion. All images were recorded digitally and every single frame (0.2 
mm) was analyzed by two expert and independent investigators who were blinded to clinical and 
laboratory values (Institute of Cardiology, Catholic University of the Sacred Heart, Policlinico 
Gemelli, Rome, Italy). At the MLA site or at culprit lesion, respectively in SA and AMI patients, 
the analysis was targeted on plaque characterization (calcified, fibrous, or lipid plaques), 
presence of plaque rupture, measurement of fibrous cap thickness, presence of intracoronary 
thrombus and intra-plaque micro channels. When a plaque contained two or more lipid-
containing quadrants, it was considered a lipid-rich plaque, and the lipid arc and the cap 
thickness were measured. Thin-cap fibroatheroma (TCFA) was defined as a lipid-rich plaque with 
a fibrous cap thickness of ≤65 µm. 
 
5.3.9.2 OCT macrophage analysis 
We assessed the presence of macrophage infiltration (MØI) in the analyzed lesions by OCT. 
Macrophages were qualitatively identified according to International Working Group for 
Intravascular Optical Coherence Tomography (IWG-IVOCT) Consensus standards [237]. In 
particular, macrophages have been visualized by OCT imaging as signal-rich, distinct, or 
confluent punctate regions that exceed the intensity of background speckle noise and generate a 
backward shadowing. For caps having a thickness <125 µm2, the depth of the region of interest 
(ROI) was matched to the cap thickness. Median filtering was performed with a 3x3 square 
kernel to remove speckle noise. In plaques with MØI, quantitative evaluation of macrophage 
content was obtained by measuring the normalized standard deviation (NSD) known to have a 
high degree of positive correlation with histological measurements of macrophage content, by 
using dedicated software provided by S. Jude medical. In particular, NSD was measured for each 
pixel within each cap using a 125 µm2 window centered at the pixel location: NSD (x,y) = [σ 
(x,y)125 µm2/(Smax-Smin)] x 100. Where NSD (x,y) is the normalized standard deviation of the 
OCT signal at pixel location (x,y), Smax is the maximum OCT image value, and Smin is the 
minimum OCT image value. Pixels within the (125 x 125) µm2 window that did not overlap with 
the segmented cap were excluded. 
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5.4 Biochemical signatures 
The biochemical profile of MDMs obtained from our study population was assessed by western 
blot and immunofluorescence methodologies. In particular we assessed transglutaminase (TG)2 
and tissue factor (TF) levels in MDMs population through western blot using primary antibody 
directed against TG2 (Cell signaling, Euroclone, Milano, Italy) (1:1000) and TF (America 
Diagnostica, Sekisui Diagnostics, Cabru, Milan, Italy) (1:500), respectively. To evaluate the levels 
of this protein in both morphotypes we used immunofluorescence technique with primary 
antibody directed against TG2 (Cell signaling) (1:100) and TF (1:200), respectively.  
Moreover, we analysed the activity of mediators releasing by our cells population. In particular, 
the activity of matrix metalloproteinase (MMP)-9 secreted by MDMs was evaluated using 
BiotrakTM activity assay system (Amersham, GE Healthcare, Milan, Italy). 
Finally, we assessed the total and free fatty acid composition of MDMs obtained from our study 
population through mass spectrometry analysis. 
5.5 Functional analyses 
The functional profile of MDMs obtained from healthy subjects and CAD patients was assessed 
by the evaluation of efferocytic capability using the efferocytic assay and the thrombin 
production by thrombin generation assay.  
 
5.6 Oxidative stress evaluation 
We also evaluated the oxidative stress of MDMs obtained from our study population by: 
- the assessment of GSH/GSSG using mass spectrometry.  
- the determination of Nuclear-realetd factor 2 (Nrf2) and heme-oxigenase 1 (HO-1) 
pathway using western blot and immunofluorescence techniques. In detail, for 
assessment of Nrf2 and HO-1 levels through western blot we used primary antibody 
direct against Nrf2 (Santa Cruz Biotechnology, DBA Italia, Milano, Italy) (1:500) and HO-1 
(Abcam, Prodotti Giann S.p.A., Milano, Italy) (1:250), respectively. For 
immunofluorescence determination we used primary antibody against Nrf2 (Cell 
signaling) (1:200) and HO-1 (Abcam) (1:100), respectively.  
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5.7 Statistical analysis 
The distribution of continuous variables was assessed by visual inspection of frequency 
histograms and with the use of the Shapiro–Wilk test. Continuous variables were expressed as 
mean±SD or median with interquartile range, if they followed a normal or non-normal 
distribution, respectively. Continuous variables were compared with unpaired t-test or Mann– 
Whitney U-test, whereas categorical variables were compared using the Chi square test or 
Fisher’s exact test, as appropriate. Paired-group comparison was performed using the paired t-
test or Wilcoxon test, as appropriate. Unpaired t-test or Mann-Whitney U-test were used for the 
comparison of continuous variables between groups; continuous variables among groups were 
compared with ANOVA or Kruskal-Wallis test, and Bonferroni’s correction for multiple 
comparison was applied and a Bonferroni-adjusted (Ba)-p-value was reported. Analysis of 
trends, according to the severity of the disease, was performed by Spearman’s rank test. 
Correlations between variables were performed using the Pearson test or the Spearman’s rank 
test, as appropriate. Intra-observer and inter-observer variability in the analysis of MØI in the 
fibrous cap were assessed by Kappa measure of agreement. Regarding the evaluation of MØI, 
Kappa measures of agreement for intra-observer and inter-observer variability were 0.89 
(p<0.0001) and 0.94 (p<0.001), respectively. Of note, all performed analyses have been adjusted 
for age and sex. All tests were two-sided. A p value <0.05 was considered to indicate statistical 
significance. All calculations were computed with the aid of the SAS software package (Version 
9.2; SAS Institute Inc., Cary, NC). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Results 
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6.1 Study population 
The principal demographic, clinical and laboratory characteristics of the patient groups and of 
healthy subjects analysed in this study are depicted in Table 2. 
   CAD group    
Variables 
Healthy 
subjects 
n=25 
SA 
n=41 
NSTEMI 
n=28 
STEMI 
n=21 
ANOVA 
all 
subjects 
ANOVA 
CAD 
patients 
only 
Demographics       
Age (years) 49±15 68±9 65±13 60±13 0.0001 0.034 
Male sex, n (%) 10 (40) 33 (81) 20 (74) 18 (82) 0.002 0.765 
BMI (kg/m²) 24.5±1.8 28.6±3.3 28.3±2.9 30.3±5.0 0.0001 0.125 
Clinical characteristics       
Current smoking, n (%) - 26 (63) 16 (59) 14 (64)  0.933 
Diabetes mellitus, n (%) - 11 (27) 12 (44) 11 (50)  0.138 
Dyslipidemia, n (%) - 21 (51) 15 (56) 11 (50)  0.916 
Hypertension, n (%) - 24 (58) 13 (48) 14 (64)  0.533 
Family history of CAD, n 
(%) 
- 19 (46) 19 (70) 8 (36)  0.043 
LVEF (%) - 55±7 51±7 52±6  0.578 
Laboratory data       
WBC (×109/l) 7.25±2.91 9.21±3.60 8.80±3.41 8.72±2.59 0.148 0.820 
RBC (×1012/l) 4.57±0.69 4.62±0.70 5.70±4.36 5.13±2.39 0.262 0.274 
Neutrophil count (×109/l) 4.63±2.50 6.41±3.21 5.90±3.29 6.03±2.19 0.122 0.769 
Lymphocyte count 
(×109/l) 
1.98±0.98 2.03±0.83 1.87±0.70 2.05±0.95 0.853 0.668 
Eosinophil count (×109/l) 0.14±0.12 0.37±1.14 0.21±0.25 0.54±1.60 0.502 0.599 
Monocyte count (×109/l) 0.49±0.20 0.63±0.23 0.58±0.27 0.62±0.23 0.094 0.698 
Basophil count (×109/l) 0.02±0.02 0.01±0.03 0.01±0.02 0.01±0.02 0.028 0.935 
Platelets (×109/l) 244±61 220±74 238±83 214±60 0.40 0.472 
hs-CRP (mg/l) 1.9 (1.4-2.6) 2.10 (1.40-3.20) 7.80 (3.35-16.95) 21.35 (10.43-30.25) 0.001 0.0001* 
Creatinine (mg/dl) 1.03±0.15 1.02±0.37 0.93±0.28 1.01±0.35 0.301 0.487 
Glycaemia (mg/dl) 105±29 124±27 123±32 141±39 0.0001 0.084 
Total cholesterol (mg/dl) 168±32 170±35 192±45 222±40 0.0001 0.0001 
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LDL (mg/dl) 113±26 97±26 119±45 141±34 0.0001 0.0001 
HDL (mg/dl) 44±12 50±15 43±10 43±10 0.017 0.033 
Triglycerides (mg/dl) 119±24 122±55 163±68 163±59 0.006 0.007 
Peak TnI (μg/dl) - 0.001 (0.001-0.002) 1.70 (0.75-7.00) 30.85 (17.10-73.75)  0.0001* 
Peak CK-MB (μg/dl) - 2.10 (1.60-3.42) 19.00 (9.45-42.65) 
231.50 (114.25-
297.75) 
 0.0001* 
Angiographic data       
Culprit or treated vessel, 
n (%) 
      
LAD - 16 (39) 22 (81) 11 (50)   
LCX - 7 (17) 2 (7) 3 (14)   
RCA - 18 (44) 3 (11) 8 (30)   
Multivessel disease, n (%) - 28 (68) 15 (56) 8 (36)  0.051 
Admission therapy       
ASA, n (%) - 14 (34) 12 (44) 8 (36)  0.692 
Beta-Blockers, n (%) - 12 (29) 11 (41) 3 (14)  0.116 
ACE-inhibitors, n (%) - 21 (51) 9 (33) 2 (9)  0.003 
Statins, n (%) - 17 (41) 6 (22) 8 (36)  0.264 
 
 
Table 2: Baseline clinical, laboratory and angiographic characteristics of healthy subject and coronary artery disease patients according to 
their clinical presentation 
Data are expressed as mean  ±  SD or median and interquartile range. p value: ANOVA t test, *Kruskal-Wallis test. 
SA, stable angina; AMI, acute myocardial infarction; CAD, coronary artery disease; BMI, body-mass index; LVEF, left ventricular ejection 
fraction; WBC, white blood cells; RBC, red blood cells; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitive C-
reactive protein; TnI, troponin-I; CK-MB, Creatine phosphokinase-MB; LAD, left anterior descending; LCX, left circumflex; RCA, right 
coronary artery; ASA, aspirin; ACE-inhibitors, angiotensin-converting enzyme-inhibitors. 
 
The study groups differ for age and sex that were considered as confounders for group 
comparisons. CAD patients had a significant higher BMI and received cardiovascular therapy. The 
risk factor were absent in healthy subjects, as stated in exclusion criteria. Regarding CAD group, 
acute patients (NSTEMI and STEMI) had more frequently a family history of CAD compared to SA. 
In addition, acute patients showed high levels of hs-CPR. 
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6.2 Morphological characterization of MDMs 
MDMs spontaneously differentiated from monocytes of healthy subjects showed two dominant 
and distinct morphotypes, spindle and round, that coexist in the same culture with a 1:1 ratio. 
MDMs of CAD patients also had two prevalent and different morphotypes, but the number of 
round MDMs was greater compared to spindle or to undefined macrophages (Figure 8A). 
Further, when analyzing the different clinical presentation groups (SA, NSTEMI and STEMI), the 
prevalence of round MDMs in STEMI patients was significantly greater than NSTEMI and SA, and 
in parallel a significant decrease in spindle MDMs was observed in this clinical conditions (Figure 
8B). 
  
 
                 
Figure 8: A) Monocyte-derived macrophage morphology in healthy subjects and CAD patients. B) Monocyte-derived macrophage 
morphology in SA patients compared to NSTEMI and STEMI patients. Data are expressed as the mean ± SD and derived from independent 
cultures obtained from 25 healthy subjects and 50 CAD patients (SA (n=19), NSTEMI (n=20) and STEMI (n=11)). *p<0.05 vs. healthy 
subjects; $ p<0.05 vs. SA; #p<0.05 as spindle and undefined MDM in STEMI patients. 
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6.3 Biochemical and functional profile assessment 
6.3.1 Efferocytosis of MDMs  
We assessed the efferocytosis of MDMs in our study groups. We found that the efferocytotic 
capacity of MDMs obtained from CAD patients (SA, NSTEMI and STEMI) was significantly lower 
compared to healthy subjects, while it was similar in SA or acute patients (Figure 9).  
 
 
 
Figure 9: Efferocytic capacity of MDMs obtained from healthy subjects and CAD patients. Data are expressed as percentage of MDMs that 
have engulfed carboxyfluorescein diacetate succinimidyl ester (CSFE)-stained apoptotic cells and derive from independent cultures 
obtained from 25 healthy subjects and 50 CAD patients (SA (n=19), NSTEMI (n=16), STEMI (n=15)). * p<0.05 vs. healthy subjects 
 
6.3.2 Evaluation of TG2 levels  
In order to verify the potential involvement of TG2, protein involved in phagosomal formation, in 
the efferocytosis of MDMs we assessed the expression of TG2. MDMs obtained from CAD 
patients showed lower levels of TG2 compared to healthy subjects (Figure 10A). 
Immunofluorescence analysis evidenced that while in healthy subjects TG2 was more abundant 
in round than spindle MDMs, in SA, NSTEMI and STEMI patients TG2 levels were similar in both 
round and spindle MDM morphotypes. In Figure 10B, representative images were shown. 
Moreover, we observed significantly lower TG2 levels in round MDMs of CAD patients (SA, 
NSTEMI and STEMI) in comparison to healthy subject round MDMs  (Figure 10C). 
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Figure 10: TG2 levels. A) TG2 was detected by western blot analysis in MDMs obtained from CAD patients and healthy subjects. β-actin was 
used as a control of protein loading. Densitometry is shown in the bar graph. Data are expressed as the mean ± SD and derive from MDMs 
obtained from 5 healthy subjects and 10 CAD patients. B) Representative images of TG2 in round and spindle MDMs obtained from healthy 
subjects and CAD patients (400× original magnification), nuclei were visualized by Hoechst 33258. C) Quantitative analysis of TG2 in round 
and spindle MDMs. Data are expressed as the mean ± SD of fluorescence intensity/µm2 (at least 3 fields, 400× magnification, were 
analysed) and derive from independent cultures obtained from 10 healthy subjects and 30 CAD patients (SA (n=10), NSTEMI (n=10) and 
STEMI (n=10)). *p<0.05 vs. healthy subjects. 
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6.3.3 Evaluation of TF levels  
We assessed TF levels in MDMs obtained from our study population by western blot analysis. 
We observed that, MDMs of CAD patients had significantly higher TF levels in relation with 
healthy subjects (Figure 11A). The immunofluorescence analysis shows an equally distribution of 
this protein in both spindle and round MDMs morphotypes in healthy as well as in patients. 
However, a significant increase in TF fluorescence intensity was detected in both MDM 
morphotypes of CAD patients in respect to their counterparts in healthy subjects (Figure 11B). In 
particular, a trend of MDM TF levels both in round and spindle morphotypes (ptrend=0.004 and 
ptrend=0.001, respectively) according to the severity of the disease from healthy subjects to SA, 
NSTEMI, and STEMI patients, was observed. The highest TF expression was found in both round 
and spindle MDMs of STEMI patients (Figure 11C).  
 
 
 
 
 
                                                          
        
 
 
 
 
 
 
 
 
 
 
 
 
 
Healthy 
subjecs 
CAD 
patients 
Healthy subjects SA NSTEMI STEMI 
B
0 
TF
/β
-a
ct
in
 
(d
e
n
si
to
m
e
tr
ic
 a
n
al
ys
is
) 
0.2 
0.4 
0.6 
0.8 
0 
1 
2 
1.2 
1.4 
1.6 
1.8 
β-actin 
Healthy subjects 
 
CAD patients 
TF 
* A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
68 
 
 
 
 
 
 
 
 
 
 
Figure 11: TF levels in CAD patients and healthy subjects. A) TF was detected by western blot analysis. β-actin was used as a control of 
protein loading. Densitometry is shown in the bar graph. Data are expressed as the mean ± SD and derive from MDMs obtained from 8 
healthy subjects and 15 CAD patients. B) Representative images TF in round and spindle MDMs obtained from healthy subjects and CAD 
patients (400× original magnification), nuclei were visualized by Hoechst 33258. C) Quantitative analysis of TF in round and spindle MDMs. 
Data are expressed as the mean ± SD of fluorescence intensity/µm2 (at least 3 fields, 400× magnification, were analyzed) and data derive 
from independent cultures obtained from 10 healthy subjects and 30 CAD patients (SA (n=10), NSTEMI (n=10) and STEMI (n=10)). * p<0.05, 
** p<0.01, vs. healthy subjects. 
 
 
6.3.4 Thrombin generation 
Enhanced antigenic expression of TF in MDMs of CAD patients displayed a functional 
consequence in thrombin generation. In fact,  CAD patients showed a reduction in the lag time 
and in the time to peak with respect to healthy subjects with no change on the peak of thrombin 
generation or endogenous thrombin potential (ETP) (Table 3). 
 
Parameters Healthy subjects CAD P value 
Lag Time (min) 14.51 ± 4.12 12.8 5± 3.73 0.04 
ETP (nM min) 1167.42 ± 287.03 1216.30 ± 256.92 0.59 
Peak (nM) 149.63 ± 63.67 178.11 ± 59.82 0.17 
ttPeak (min) 18.17 ± 4.90 14.93 ± 4.21 0.04 
VelIndex  (nM/min) 49.51 ± 35.31 68.12 ± 38.37 0.14 
 
Table 3: Thrombin generation evaluated using Thrombinoscope in healthy subjects (n=16) compared to CAD patients (n=20).   
Time to peak (ttPeak), endogenous thrombin potential (ETP), and velocity index of propagation phase (VelIndex) 
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6.4 Matrix Metalloproteinase-9 Activity 
We analyzed the MMP-9 activity in MDMs obtained from healthy subjects and CAD patients. We 
observed that MMP-9 activity in MDMs was higher in CAD patients than in healthy subjects. In 
particular, when we analyzing the different clinical presentation (SA, NSTEMI and STEMI), we 
observed a progressive increase in MMP-9 activity from SA to acute patients reaching a maximum in 
STEMI patients (ptrend=0.004) (Figure 12).  
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Figure 12:  MMP-9 activity in SA, NSTEMI and STEMI patients and healthy subjects. Data are expressed as the mean ± SD derived from 
independent cultures obtained from 10 healthy subjects and 30 CAD patients (SA (n=10), NSTEMI (n=10) and STEMI (n=10)). * p<0.05 vs. 
healthy subjects.  
 
 
6.4.1 Evaluation of GSH/GSSG ratio 
In order to evaluate the oxidative stress status in the study population, we measured in MDMs 
the levels of the reduced and the oxidized form of glutathione, whose ratio is a recognized index 
of oxidative stress. The results are showed in Figure 13. The GSH/GSSG ratio was decreased in 
CAD patient respect to healthy subjects. When analyzing the different clinical presentation 
groups (SA, NSTEMI and STEMI) the GSH/GSSG ratio was lower in MDMs of STEMI patients in 
respect to healthy subject, SA and NSTEMI patients (ptrend=0.022). 
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Figure 13: GSH/GSSG evaluation in SA, NSTEMI and STEMI patients and healthy subjects. Data are expressed as the mean ± SD derived from 
independent cultures obtained from 5 healthy subjects and 15 CAD patients (SA (n=5), NSTEMI (n=5) and STEMI (n=5)). * p<0.05 vs. healthy 
subjects.  
 
6.4.2 Evaluation of Nrf2 and HO-1 levels 
In order to evaluate the response of MDMs to oxidative stress, we evaluated the activation of 
Nrf2/HO-1 pathway. We observed that Nrf2 was higher in MDMs of CAD patients with respect to 
those of healthy subjects (Figure 14A). These data are confirming by immunofluorescence 
(Figure 14B). In detail, when we analyzed the distribution of this transcription factor in different 
clinical presentation (SA, NSTEMI and STEMI), an increasing Nrf2 (ptrend round=0.035, ptrend 
spindle=0.121) in NSTEMI and STEMI was observed (Figure 14C). This behavior was mirrored by 
Nrf2 target protein. HO-1 was higher in CAD patients (Figure 15A and 15B) and a trend according 
to the severity of clinical presentation was detected (ptrend round<0.001, ptrend spindle=0.003). 
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Figure 14:  Nrf2 levels in CAD patients and healthy subjects. (A) Nrf2 was detected by western blot analysis. β-actin was used as a control of 
protein loading. Densitometry is shown in the bar graph. Data are expressed as the mean ± SD and derive from MDMs obtained from 11 
healthy subjects and 17 CAD patients. (B) Representative images of Nrf2 in round and spindle MDMs obtained from healthy subjects and 
CAD patients (400× original magnification), nuclei were visualized by Hoechst 33258. C) Quantitative analysis of Nrf2 in round and spindle 
MDMs. Data are expressed as the mean ± SD of fluorescence intensity/µm2 (at least 3 fields, 400× magnification, were analyzed) and data 
derive from independent cultures obtained from 10 healthy subjects and 30 CAD patients (SA (n=10), NSTEMI (n=10) and STEMI (n=10)). 
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Figure 15:  HO-1 levels in CAD patients and healthy subjects. (A) HO-1 was detected by western blot analysis. β-actin was used as a control 
of protein loading. Densitometry is shown in the bar graph. Data are expressed as the mean ± SD and derive from MDMs obtained from 11 
healthy subjects and 17 CAD patients. (B) Representative images of HO-1 in round and spindle MDMs obtained from healthy subjects and 
CAD patients (400× original magnification), nuclei were visualized by Hoechst 33258. C) Quantitative analysis of HO-1 in round and spindle 
MDMs. Data are expressed as the mean ± SD of fluorescence intensity/µm2 (at least 3 fields, 400× magnification, were analyzed) and data 
derive from independent cultures obtained from 10 healthy subjects and 30 CAD patients (SA (n=10), NSTEMI (n=10) and STEMI (n=10)).  
* p<0.05, ** p<0.01, *** p<0.001 vs. healthy subjects. 
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6.5 Fatty acid composition 
In order to evaluate if the lipid content of MDMs could influence the oxidative stress status and 
the efferocytic capacity of these cells, we evaluated the total fatty acid composition of MDMs 
obtained from healthy subjects and CAD patients. As show in Figure16 no differences in fatty 
acids composition (Figure 16A and B), desaturation index (Figure 16C) and membrane fluidity 
index (MFI) (Figure 16D) between the study groups were present.  
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Figure 16: Fatty acids profile of MDMs obtained from healthy subjects (n=10), SA (n=11), NSTEMI (n=11) and STEMI (n=10) patients. 
Unsatured (A) and Satured (B) fatty acids of MDMs purified from the four experimental groups. C) Desaturation index as ratio of C18:0 
(stearic acid)/C18:1 (oleic acid). D) MFI as ratio of C18:1 (oleic acid)/C18:2 (linoleic acid). Data are expressed as the median ± E.S. 
Nevertheless, if we grouped patients, we observed a positive correlation between GSH/GSSG 
ratio and the membrane fluidity index (MFI) in both healthy subjects and CAD patients, 
indicating the existence of a relationship between oxidative stress and lipid composition (Figure   
17A e B, p<0.0001 and p=0.0003, respectively).  
 
 
 
Figure 17: Correlation between GSH/GSSG ratio and MFI (stearic acid/oleic acid) in healthy subjects (n=10) (A) and CAD patients (n=32) (B) 
 
MFI positively correlate also with efferocytosis in both study groups, underlying the importance 
of lipid composition in this process (Figure 18A e B). 
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Figure18: Correlation between efferocytosis and MFI (stearic acid/oleic acid) in healthy subjects (n=10) (A) and in CAD patients (n=32) (B) 
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6.6 MDMs: biochemical and morphological characteristics and OCT 
plaque features 
 
Representative OCT images of in vivo coronary atherosclerotic plaques are showed in Figure 19. 
 
 
 
 
 
 
 
 
Figure 19: Representative OCT images of coronary atherosclerotic plaque. (A) Stable fibrous coronary plaque. (B) High-risk thin-cap 
fibroatheroma (white arrows). (C) Coronary rupture plaque with macrophage infiltration (white arrows). 
 
 
At OCT analysis, acute patients present more frequently a lipid plaque, a ruptured plaque, a thin 
cap fibroatheroma and the presence of thrombus (white and red) with respect to SA patients. 
Moreover, acute patients present plaque with grater lipid content compared to those of SA, 
evidenced by higher number of lipid quadrant and lipid arc degree. Furthermore, these patients 
showed higher numbers of microchannels and higher macrophage content respect to SA 
patients. On contrary, SA patients present more frequently a fibrous and calcific plaque in 
respect to acute patients (Table 4). 
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Variables 
SA 
(N=26) 
AMI 
(N=24) 
p VALUE 
    
Lipid plaque, n (%) 15 (57) 22 (92) 0.01 
Fibrous plaque, n (%) 9 (35) 2 (8) 0.04* 
Calcific plaque, n (%) 7 (27) 2 (8) 0.14* 
Plaque rupture, n (%) 6 (23) 18 (75) 0.01 
MLA, mm2 1.59 (0.71-3.85) 1.54 (0.70-3.75) 0.99 
TCFA, n (%) 8 (31) 19 (79) 0.001 
Thrombus, n (%) 2 (8) 20 (83) 0.0001* 
White, n (%) 1 (4) 18 (75) 0.0001* 
Red, n (%) 1 (4) 7 (29) 0.02* 
Lipid quadrants, n 2.1±1.0 3.1±1.6 0.0001 
Lipid arc degree ° 135 (87-265) 269 (161-280) 0.0001 
Presence of microchannels, n (%) 4 (15) 15 (63) 0.0006* 
Macrophage infiltration 
detection, n (%) 
14 (54) 22 (92) 0.001 
Macrophage NSD 3.45±1.01 6.19±1.95 0.001 
 
Table 4. Optical coherence tomography features of coronary artery disease patients according to the clinical presentation 
Data are expressed as mean ± SD or median and interquartile range. p value: Wilcoxon testfor quantitative variables; *Fisher test. 
MLA, minimal lumen area; TCFA, thin-cap fibroatheroma; NSD, normalized standard deviation.  
 
6.6.1 MDMs morphology  
We wanted to evaluate if there were some associations between the frequency of MDM 
morphotypes observed in vitro in CAD patients and plaque features in vivo assessed by OCT.  
We observed  that the prevalence of round MDMs was significantly higher in patients presenting 
a thin cap fibroatheroma (TCFA), a lipid plaque, a ruptured plaque, and a presence of thrombus 
(Figures 20A-20D). Moreover, the identification of high number of intra-plaque macrophages 
was associated with a high prevalence of round MDMs (Figure 20E) and the latter positively 
correlated with macrophage content which was represented by NSD parameter (Figure 20F). 
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Figure 20: OCT plaque features and frequency of round MDM morphotype. Association between round MDM morphotype and thin-cap 
fibroatheroma, TCFA(A), plaque lipid content(B), fibrous cap integrity(C), presence of thrombus(D), presence of intra-plaque macrophages 
(E), and correlation between macrophage content (normalized standard deviation (NSD)) (F) detected by means OCT in in vivo plaque. 
*p<0.02; **p<0.002; ***p<0.0005; #p<0.0001. 
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6.6.2 MDMs TF levels  
High TF levels observed in in round and spindle MDMs of CAD patients are associated with the 
presence of a ruptured plaque (Figure 21A), of thrombus (B) and of intra-plaque macrophages 
(C) analyzed by OCT.  
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Figure 21: Correlation between TF levels in round and spindle MDMs and ruptured plaque (A), presence of thrombus (B) and intraplaque 
macrophages content (C). 
 
6.6.3 MDM oxidative stress profile and plaque features analyzed by OCT 
In order to highlight if existed some relationships between high oxidative stress levels observed 
in MDMs obtained in vitro and coronary plaque features detected in vivo by OCT, we analyzed 
possible association between these parameters. We observed that there was an association 
between GSH/GSSG and the presence of ruptured plaque (Figure 22A). Moreover, we showed 
that patients with high levels of HO-1 more frequently displayed a ruptured plaque (Figure 22B), 
a reduction in TCFA (Figure 22C) and presence of thrombus (Figure 22D). In addition, we 
observed a correlation between HO-1 levels in both MDM morphotypes with macrophage 
content (NSD) (Figure 22E) and max lipid arc (Figure 22F). 
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Figure 22: OCT plaque features and oxidative stress. Association between GSH/GSSG ratio and presence of ruptured plaque (* p<0.05) (A); 
association between HO-1 level and fibrous cap integrity (B), thin cap fibroatheroma (TCFA) (C), presence of thrombus (D); correlation 
between HO-1 levels in round and spindle MDM and macrophage content (E) and max lipid arc (F) detected by means OCT in in vivo 
plaque. 
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7. Discussion 
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Macrophages are instrumental to the atherogenic process and contribute to its initiation, 
progression and symptomatology. They comprise heterogeneous populations with several 
subtype having different, even opposite functions. This heterogeneity has been detected also in 
atherosclerotic plaque where the prevalence of a specific macrophage phenotype may have 
either harmful or beneficial function in the progression or stabilization of the plaque [238, 239]. 
Studies on tissue-resident macrophages are very challenging for the difficulties in macrophage 
isolation without affecting their viability. In addition, human coronary atherosclerotic plaque is a 
compartment not easy to obtain. Various in vitro models currently used to obtain macrophages 
as monocytic cell line exposed to differentiating agents do not, however, adequately reflect the 
heterogeneity and the plasticity of primary tissue macrophages [240], thus questioning whether 
deductions drawn by these approaches may be appropriate for tissue macrophages. 
Macrophages obtained from a spontaneous differentiation of monocytes isolated from 
peripheral blood are commonly accepted as a good surrogate of macrophages infiltrating tissue. 
On these bases, we have cultured monocytes for 7 days in a medium containing 10% of 
autologous serum to preserve the individual trait of each donor. A previous study from our 
group have demonstrated in MDMs obtained from healthy subjects, the presence of two 
dominant subsets different in morphology (spindle- or round-shaped) and in function [241]. 
Notably, these phenotypes exhibit a number of features that resemble M1 and M2 profile, with 
round MDMs showing functional traits reminiscent of the non-inflammatory and reparative M2 
phenotype, whereas spindle MDMs exhibiting a pro-inflammatory profile and expressing genes 
driving lymphocyte activation. Based on this model, in the present study, we have characterized 
MDM morphotypes (round and spindle) in consecutive CAD patients, in order to delineate a 
biochemical and functional profile of different MDM morphotypes and their contribute in plaque 
instability.  
In contrast to that observed in healthy subjects, who are characterized by a similar frequency of 
the two dominant morphotypes, spindle and round cells, MDMs obtained from CAD patients 
showed a prevalence of round ones. 
Interestingly, the prevalence of round MDMs in CAD patients was grater, their efferocytic ability 
was reduced. Since in a previous study we have demonstrated that in healthy subjects round 
MDMs are better efferocytes than spindle [241], this observation suggests that CAD condition is 
Discussion 
85 
 
associated with a particular round phenotype exhibiting reduced anti-inflammatory properties 
compared to round MDMs of healthy subjects.  
Atherosclerotic lesion is a complex, debris-rich microenvironment in which apoptosis rates are 
very high and engulfment mechanisms are continuously solicited. Therefore, blockage of 
efferocytosis has strong effects with a worsening of inflammation and increased atherosclerosis. 
It was demonstrated that the invalidation of only one pathway involved in efferocytic process 
leaded to a marked accumulation of apoptotic cells, even in early lesions, with the consequent 
increase of necrotic core and plaque growth [107, 242-244]. 
It is well known that, at atherosclerotic plaque level, efferocytosis is impaired and the efferocytic 
rate is related to atherosclerotic lesion stage [88]. In advanced atherosclerotic lesions the 
presence of inefficient mechanism for the removal of apoptotic cells by macrophages were 
documented by the occurrence of apoptotic debris in the extracellular compartment and the 
high numbers of free apoptotic cells [245]. Several factors may impaired the phagocytosis of 
apoptotic cells by macrophages in atherosclerotic plaque, including the cytoplasmic overload of 
apoptotic cells, the oxidative stress, the competitive inhibition by oxidized LDL for the same 
receptors on the macrophages [125].  
Based on in vivo study on animal model, an additional mechanism mediated by TG2 was 
described [154, 246, 247]. TG2 is a protein-cross-linking enzyme expressed in endothelial cells 
and MDMs and its activity is needed for the formation of an efficient phagocyte during 
efferocytosis [106]. Accordingly, TG2 fundamentally impairs efferocytosis in macrophages, in 
part through the activation of latent TGF-β, which in turn facilitates efferocytosis [154, 248]. In 
addition, in the absence of TG2, the integrin β3 das not recognize correctly the apoptotic cell, 
the formation of “phagocyte portal” is less efficient and the portals that are formed take up the 
apoptotic cells at a slower rate [154]. Moreover, in a recent paper, we have demonstrated that 
the inhibition of TG2 in MDMs reduces the efferocytosis via mechanisms involving CD14 and SR-
AI, receptors involved in the tether and uptake of apoptotic cell, respectively [153]. This 
observation suggests that a mechanism of cross-talk among efferocytic pathways exists and that 
the deletion of critical players impact the phagocytosis also via other receptors [249]. In the 
present study we found that TG2 was more expressed in round than spindle MDMs of healthy 
subjects, supporting the notion that round MDMs are mainly involved in efferocytosis, as 
previously described [241]. In CAD patients, a marked reduction of TG2 levels respect to healthy 
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subjects is observed, indicating that the lower efferocytosis observed in CAD may be in part 
related to TG2 expression. Numerous  regulators of efferocytosis pathways have been shown to 
exert strong effects on atherosclerosis progression [250] and the current knowledge on the 
several molecular mechanisms involved in efferocytosis, the different efferocyte subsets and 
their relationship with the immune system, require further investigation in order to highlight the 
determinants of plaque progression and plaque instability. 
It is known that the accumulation of macrophage and apoptotic cells in atherosclerotic plaque 
favor rupture of fibrous cap, due to secretion of pro-inflammatory cytokines and proteolytic 
enzymes, and thrombus formation due to release of TF [251, 252]. High levels of TF are 
expressed in atherosclerotic plaque associated with both cellular and acellular regions [171, 253-
256]. TF is the key element in the activation of the extrinsic pathway of the coagulation cascade 
and plays a critical role in atherosclerotic plaque thrombogenicity, as TF is needed for thrombin 
generation and subsequent thrombus formation. In line with these observations, unstable 
lesions contain more TF than stable lesions, mostly in macrophage-rich regions close to the 
necrotic core [171]. Moreover, Lee et al. have shown that TF was markedly expressed at the site 
of rupture in ACS patients, with a co-localization of TF with CD68 positive cells, suggesting that 
macrophages are the major source of TF in ruptured plaque [257]. However, TF was also 
expressed in SMC and extracellular space, indicating that it can be derived from other sources 
[171]. Furthermore, has been reported that TF expression in lipid-rich plaque was more than 
threefold compared with fibrous plaque and its activity in the acellular lipid core was mainly 
associated with apoptotic microparticles of monocytic and lymphocytic origin, suggesting a link 
between inflammation, apoptosis and thrombogenicity [258]. In addition, previous studies have 
shown that not only TF expressing monocytes but also TF plasma levels are higher in ACS than in 
SA patients [259-261]. It has been suggested that circulating TF may potentiate and propagate 
the thrombogenic stimulus represented by vessel wall-associated TF, resulting in the formation 
of larger and more stable thrombus, and it may bind cellular receptors, upregulating the 
inflammatory response [262, 263]. In our study, we show that MDMs obtained from CAD 
expressed higher TF levels compared to MDMs of healthy subjects and, as evidenced by 
immunocytochemical experiments, this protein is equally distributed between round and spindle 
cells in healthy subjects as well as in CAD patients.  A progressive increase going from healthy 
subjects to SA and ACS patients was observed in TF expression with a peak in STEMI patients.   
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These findings indicate that TF expression may contribute to the severity of coronary syndrome 
triggering atherothrombosis. This enhanced antigenic expression of TF displayed a functional 
consequence in thrombin generation. Indeed, CAD patients showed a reduction in the lag time 
and in the time to peak with respect to healthy subjects with no change on the peak of thrombin 
generation or endogenous thrombin potential. The difference observed between patients and 
healthy subjects, suggests a potential greater contribution to thrombus formation in this patient 
setting. Taken together, these findings indicate that TF expression may contribute to the severity 
of coronary syndrome triggering atherothrombosis.   
An increasing body of evidence have suggested that oxidative stress is closely associated with 
atherosclerotic progression and plaque instability [264, 265]. Oxidative stress is considered a 
major mechanism involved in endothelial dysfunction and ROS production is associated to the  
cardiovascular risk factors such as hypertension, diabetes, smoking, and dyslipidemia [266]. In 
artery wall ROS generation promotes and activates several pathological pathways involved in 
atherosclerosis, including lipids oxidation, expression of adhesion molecules, stimulation of SMC 
proliferation and migration, cell apoptosis, activation of metalloproteinase [267-270]. 
Accumulation of ROS in the cell induces irreversible damage of cellular component, as proteins, 
lipids, and DNA, generally leads to necrosis. To limit the impact of oxidative stress and to protect 
vital cellular components, cells activate several antioxidant systems and among them GSH is the 
most important endogenous antioxidant involved in the maintenance of intracellular redox 
balance. GSH depletion is a feature of many disease and several studies have evidenced an 
imbalance between GSH and GSSG in cardiovascular disease both in human [271] and in animal 
models [272]. Moreover, macrophages GSH levels are inversely related to oxidation of LDL [273]. 
In addition to the contribute of GSH depletion in atherosclerotic process, there is also evidence 
of GSH reduction in platelet in condition associated with increased risk of thrombosis [274]. The 
ratio between GSH/GSSG is commonly used as an indicator of oxidative status [275] and in 
accordance with the demonstration of a decrease of this ratio in whole blood of CAD patients 
[276] we have detected a progressive decrease of this oxidative stress marker in MDMs obtain 
from SA, NSTEMI and STEMI patients, respectively. Increase of oxidative stress activates several 
redox-sensitive signaling molecules pathways converging in the regulation of transcription 
factors including Nrf2, AP-1, NF-kB, HIF-1, which induce the expression of gene involved in the 
detoxification of oxidizing molecules to maintain cellular homeostasis. Nrf2 is a pleiotropic 
Discussion 
88 
 
transcription factor that regulate the expression of a numerous antioxidant proteins to induce 
cytoprotective responses to oxidative and electrophilic stress [277, 278]. Increasing evidence 
strengthens the antiatherogenic role of Nrf2 to preserve the vascular integrity and endothelial 
function, for example, sustaining the release of NO and protecting from apoptosis [279-285]. 
Moreover, the activation of Nrf2 protects the human coronary artery endothelial cells against 
oxidative challenge [286]. In macrophages has been demonstrated that the exposure to ox-LDL 
increase Nrf2 expression which indirectly safeguards the cells from ox-LDL-mediated injury via 
antioxidants and phase 2 enzyme induction [287]. The evidence that the absence of Nrf2 in mice 
high fat diet myeloid-derived macrophages increase foam cell formation and atherosclerosis 
progression, further support the protective role of Nrf2 in atherogenesis [288, 289]. Although 
substantial evidence sustains the antiatherogenic role of Nrf2-mediated signaling pathways, 
some authors have reported that Nrf2 deficiency in mice leads to decreased atherosclerotic 
lesion in Apo E null mice, suggesting its expression may play a pro-atherogenic role [290-292]. 
This effect could be related to increased levels of plasma non-HDL cholesterol, likely via 
enhanced lipogenesis [291, 293], upregulation of CD36 scavenger receptor with increase of lipid 
uptake and foam cells formation [291, 294], increased expression of IL-1α in macrophage which 
may induce monocyte migration to the lesion [292, 295]. The signaling pathways Nrf2-mediated 
are very complex and the specific conditions in which Nrf2 attenuates or stimulates 
atherosclerosis are unclear. It appears that the level of regulation upon these responses is 
important indeed the deletion of antioxidant genes as HO-1 results in exacerbation of 
atherosclerosis; in contrast, the deletion of Nrf2 transcription factor, reduces atherosclerosis 
progression [296]. In the present study, we have evidenced augmented levels of Nrf2 in MDMs 
of CAD patients respect to healthy subjects, with a significant increase in NSTEMI and STEMI 
patient. In healthy subjects, the levels of this transcription factor are very low and feeble 
fluorescence is detected in the cytosol of the cells. This is in line with its cytosolic localization in 
basal condition, where Nrf2 is associated to Keap-1protein, which induces its ubiquitination and 
proteasomal degradation. Activation of Nrf2 in response to stress signals implicates the 
dissociation from Keap-1 and the translocation into nucleus to explicate its transcriptional 
activity [297]. In addition, activation of Nrf2 in response to stress signals is dependent on 
mechanism that increase its stability, leading to its accumulation in the cells [298, 299]. In CAD 
patients, a marked increase of fluorescence intensity, localized predominantly into the nucleus 
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of MDMs, was detected, suggesting an increase in Nrf2 activity in patients in respect to healthy 
subjects. The increase in Nrf2 expression in CAD patients goes in parallel with the expression of 
HO-1. Among the Nrf2 target genes HO-1 is significantly expressed in all main cell types present 
in atherosclerotic plaque, as macrophages, endothelial cells, SMC [300, 301]. The important 
protective role of HO-1 against human atherosclerotic lesions has been emphatized in 
population genetic studies, which have evidenced that a polymorphism in the promoter region 
of human HO-1 gene is associated to susceptibility for atherosclerosis [302-304]. HO-1 deficiency 
is very rare in humans, but the autopsy case report of HO-1 deficient boy who exhibited 
hyperlipidemia, foam cells in the liver, fatty streak and fibrous plaque in the aorta, suggests the 
role of HO-1 against atherogenesis [305, 306]. It has been evidenced that HO-1 deficiency lead to 
high levels of circulating heme with damage to vascular endothelium [307], however, it is 
unclear if these effects can be only attributable to HO-1 deficiency. 
In animal studies, HO-1 induction prevent vulnerable plaque formation reducing the necrotic 
core and the lipid content, and increasing SMC accumulation in the intima and the fibrous cap 
thickness [225]. Moreover, immunohistological studies on human atherosclerotic lesions showed 
that HO-1 is mainly expressed by macrophages/foam cells residing in the neointima. Also in our 
experimental conditions, macrophages express appreciable levels of this protein, which is 
present in both morphotypes, with higher levels in spindle cells in respect to round.  
It is known that membrane lipid composition profoundly affects many cell functions and several 
studies have reported the numerous immunological effects of fatty acids [308]. In particular, in 
macrophages has been demonstrated that fatty acids modulates all the known defense 
mechanisms of these cells, including phagocytosis, cytokine production and antigen presentation 
[233, 309, 310]. Changes in fatty acid composition of cellular membranes may induce 
modification of the physical properties such as membrane fluidity that results in effects on cell 
signaling pathways and gene expression [308]. In particular, the degree of fatty acids 
insaturation in cell membrane modulates the membrane fluidity, which may influence 
phagocytosis in macrophages [311, 312]. The exposure to either linoleic acid or α-linolenic acid 
increased phagocytosis of E. coli by macrophage cell line and this increase has been linked to an 
augmentation in plasma membrane PUFA content [313]. In our study we have detected a 
reduction of efferocytosis in MDMs of CAD patients respect to healthy subjects and a positive 
correlation with MFI has been reported. However, no significant difference in fatty acids 
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composition was evidenced between CAD patients and healthy subjects. This discrepancy might 
be due to the exiguous number of patients analyzed, the influence of dietary regimens and the 
ongoing pharmacological treatments. It is known that diet is one of the major factor that 
influence the fatty acids composition of the cells, as well as the statin treatment can modulate 
the MFI and the DI [314]. Therefore, a positive correlation between GSH/GSSG ratio and MFI has 
been observed, suggesting that a condition of oxidative stress may alter the membrane fluidity 
with consequences in activation or deactivation of signaling pathways resulting in a reduced 
efferocytosis.  
The identification of unstable plaque is a crucial point in risk stratifying patients for acute 
coronary event. OCT is an imaging modality that permits to identify high risk plaque in vivo. In 
fact, OCT allows high resolution imaging of coronary atherosclerotic plaque morphology and 
composition giving important information to recognize the vulnerable plaques at high risk of 
rupture, which could cause acute coronary events and sudden death. OCT is able to detect the 
sites of plaque vulnerability and distinguish the differences in plaque composition with high 
degree of sensibility and specificity compared to histopathology [315, 316]. In particular, through 
OCT it is possible visualize and quantify macrophage (NSD) [317] and lipids content [316], fibrous 
cap thickness [318] and the presence of ruptured plaques and intraluminal thrombi [319]. From 
autopsy studies, it is well known that the vulnerable plaque has certain peculiar characteristics 
including: thin fibrous cap (<65 µm) [320] large lipid pool and inflammatory contest with 
activated macrophages near the fibrous cap. Indeed, the majority (about 80%) of plaques that 
cause acute coronary syndromes have a point of rupture at the level of an inflamed thin fibrous 
cap [321, 322]. 
Several in vivo studies have demonstrated the relationship between plaque morphology 
analyzed by OCT and patient outcome. In particular, it was observed that acute CAD patient 
present more frequently a lipid plaque [323], a ruptured plaque [324], a TCFA [324] and 
presence of thrombi [323]. Moreover, Tearney also observed that acute CAD patients presented 
atherosclerotic plaques with higher macrophage density compared to the plaques of SA patients. 
On contrary, fibrous and calcific plaques were more frequently in SA in respect to acute CAD 
patients [324]. According to these observations, in our study we found that acute patients 
present more frequently a lipid plaque with a thin cap fibroatheroma, a ruptured plaque, and 
the presence of thrombus with respect to SA patients. Moreover, acute patients present plaques 
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with grater lipid and higher macrophage contents compared to those of SA. On contrary, SA 
patients present more frequently a fibrous and calcific plaque in respect to acute patients.  
As previously mentioned, inside atherosclerotic plaque macrophages are an heterogeneous 
population in term of morphology and function [238] and the prevalence of a specific 
morphotype could influence the progression and/or regression of the disease [239]. In our study, 
we found that the prevalence of round morphotype in MDMs obtained from CAD patients is 
associated with the presence of vulnerable plaque analyzed by OCT. In particular, the prevalence 
of round morphotype is associated with the presence of TCFA, lipid plaque, high presence of 
intra-plaque macrophages, ruptured plaque, and presence of thrombus. In addition, a positive 
correlation between NSD and round MDMs was found. The extended lipid core of vulnerable 
plaque is highly thrombogenic for the presence of cells as macrophages, monocytes, SMC, that 
upon activation, express high levels of TF. It has been reported that TF expression in lipid-rich 
plaque was more than threefold compared with fibrous plaque and its activity in the acellular 
lipid core was mainly associated with apoptotic microparticles of monocytic and lymphocytic 
origin, suggesting a link between inflammation, apoptosis and thrombogenicity [258]. Moreover, 
unstable lesions contain more TF than stable lesions, mostly in macrophage-rich regions close to 
the necrotic core [258]. Furthermore, it was observed that macrophage-derived foam cells in 
atherosclerotic plaque expressed TF and his expression was increased in lipid-rich plaque 
compared with fibrous plaque [258, 325]. Accordingly, we found that the high TF levels in round 
and spindle MDMs of CAD patients are associate with high intra-plaque macrophages content, 
presence of ruptured plaque, and thrombus formation at OCT investigation. This is in line with 
the observation that TF levels are higher in atheroma from patients with unstable angina than 
with SA [257].  TF is constitutively expressed by cells surrounding the vessel wall, including SMC 
and fibroblasts, but also in monocytes and macrophages in which a condition of oxidative stress 
may induce the expression of TF via NF-κB activation, an oxidative-stress sensitive transcription 
factor [326].  It is known that oxidative stress contribute to plaque vulnerability through the 
activation of several pathways as lipid oxidation, induction of MMP, expression of adhesion 
molecules and SMC proliferation and migration [267-270, 327]. According to this knowledge, we 
observed that patients that presented MDMs with high oxidative stress level, more frequently 
showed a ruptured plaque. It is also known that antioxidant molecules, such as HO-1 are 
expressed into atherosclerotic plaque, trying to avoid the oxidative damages. In fact, Cheng et al. 
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have demonstrated that, in human carotid plaques, HO-1 is more present inside vulnerable 
plaque in respect to stable ones [225]. On this basis, it is proposed that the high expression of 
HO-1 detected in vulnerable plaque represent a compensatory atheroprotective response, in 
which HO-1 try prevent plaque instability by reducing lipid deposition and necrotic core 
expansion and by prolonging SMC survival in the fibrous cap [225]. Moreover, a previous paper 
has demonstrated that the HO-1 protein levels expressed on lymphocytes and monocytes 
isolated from patients at different CAD stages reflected the severity of the pathology 
angiographically detected, with a significant increase from SA to unstable and acute myocardial 
infarction [224, 328]. Accordingly, patients with highest levels of HO-1 in MDMs, more 
frequently show a vulnerable plaque characterized by a thin fibrous cap fibroatheroma, and 
increase in macrophage and lipid content. In addition, higher levels of HO-1 are detected in 
MDMs of patient with rupture plaque and with the presence of thrombus in respect to patients 
with non-ruptured plaque and without thrombus formation. 
In summary, our study shows that MDMs of CAD patients have a peculiar morpho-phenotype 
profile, which is characterized by a predominance of round cells. MDMs of CAD patients showed 
differences in biochemical and functional signature compared to healthy subjects. In detail, they 
exhibit a reduced anti-inflammatory property evidenced by a less efferocytic capacity going in 
parallel with the decreased expression of TG2. Furthermore, MDMs of CAD patients display high 
propensity for thrombogenicity, characterized by the increase of TF levels resulting in a higher 
capacity to generate thrombin (Scheme 1).   
Finally, we have demonstrated that CAD condition is characterized by an oxidative stress status 
not only at systemic levels but also in MDMs. In this cellular compartment, oxidative stress can 
modify some physicochemical properties of the lipid membrane with an alteration of its fluidity, 
feature important for an efficient phagocytosis process. Indeed, a positive correlation between 
membrane fluidity, expressed as MFI, and oxidative stress status, as well as MFI and capacity to 
engulf apoptotic cells, was found. This specific cellular profile detected in in vitro obtained 
MDMs is associated with the detection of high-risk and rupture-prone coronary plaques, at OCT 
investigation (Scheme 1). 
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Scheme 1. MDMs biochemical and functional characteristics and OCT plaque features. TG2: transglutaminase 2; TF: tissue factor; GSSG: 
oxidized form of glutathione; GSH: reduced form of glutathione; Nrf2: nuclear factor erythroid 2–related factor 2; HO-1: heme oxygenase-
1; MFI: membrane fluidity index. 
 
Revealing the functional characteristics of individual macrophage phenotypes may lead to a 
better understanding of their contribution to coronary atherosclerosis. Different MDM 
phenotypes might be novel diagnostic and therapeutic target for a possible pharmacological 
treatment able to counteract the progression of atherosclerosis.  
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Our study evidenced that macrophages obtained from spontaneous differentiation of monocytes 
isolated from peripheral blood of healthy subjects and patients with coronary disease (stable 
and instable) showed different biochemical and functional profiles. In particular, macrophages 
obtained from CAD patients presented reduced anti-inflammatory and increased pro-thrombotic 
proprieties in respect to those of healthy subjects. Moreover, this specific cellular profile 
detected in in vitro model was associated with high-risk and rupture-prone coronary plaques, at 
OCT investigation. These differences may derived from the characteristics of the environment in 
which they differentiate into macrophages, such as serum composition (i.g. cytokines and 
chemokines levels) or from a priming that monocytes receive into the blood stream that direct 
them to differentiate toward a pro-atherogenic phenotype. It is known that in vivo circulating 
monocytes are exposed to the systemic environment, including metabolic factors, such as 
dyslipidemia, and inflammatory molecules produced by other organs and tissues, and may thus 
be programmed to sustain the chronic inflammation related to atherosclerosis. So we will focus 
our attention on circulating monocytes in order to verify if they are able to mirror the profile of 
monocyte-derived macrophages and in this way to contribute to the progression of coronary 
atherosclerosis. 
Circulating monocytes are a compartment easily obtainable and could represent a diagnostics 
and predictive marker and a therapeutic target for atherosclerotic disease. Therefore, a 
characterization of monocytes isolated from peripheral blood of healthy subjects and patients 
with stable angina or acute coronary syndrome may lead to better understanding their 
contribution to coronary disease. Hence, we will assess the genomic, proteomic, metabolomics 
and functional profile of these cells in relation to the clinic characteristics of enrolled population, 
the MDMs profile, the plaque morphology and the macrophage content of atherosclerotic lesion 
evaluated by OCT.  
The monocytes signature may allow the better risk stratification and may permit the early 
prognosis. In addition, these results may help to identify monocyte markers able to predict the 
progression of the disease.  
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